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ABSTRACT 
The methodology of lithiation-halogenation of purines have been previously studied in our 
group
1-3 
and others.
4-12
 
The present thesis is focused on the methodology of lithiation-halogenation of 6-chloro-9-
substituted purines and 9-substituted adenines via 8-purinyl anions (Scheme A, step 2). As an 
extension of this work, lithiation-halogenation of 7-allyl-6-chloro-7H-purine was also 
investigated. 
Various methods for the step prior to lithiation-halogenation, N-alkylations were also studied 
(Scheme A, step 1). 
 
Scheme A. Reaction route  
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ABBREVIATIONS 
Ac  Acetyl 
Ar  Aryl 
BuLi  Buyllithium 
DCM  Dichloromethane 
DEAD  Diethyl azodicarboxylate 
DMA  Dimethylacetamide 
DMF  N,N-dimethylformamide 
DNA  Deoxyribonucleic acid  
EI  Electron impact (MS) 
EDG  Electron donating group 
ESI  Electronsprayionisation (MS) 
EtOAc Ethyl acetate 
EtOH  Ethanol 
EWG  Electron withdrawing group 
HMBC Heteronuclear Multiple Bond Coherence 
HMQC Heteronuclear Multiple Quantum Coherence 
HRMS High Resolution Mass Spectra 
J  Coupling constant (NMR) 
LC-MS Liquid chromatography–mass spectrometry 
LDA  Lithium diisopropylamide 
MS  Mass Spectrometry 
n.d.  Not determined 
NOE  Nuclear Overhauser Effect (NMR) 
NOESY Nuclear Overhauser Effect Spectroscopy (NMR) 
ppm  Parts per million 
R-X  Alkyl halide 
RNA  Ribonucleic acid 
SNAr  Nucleophillic Aromatic Substitution 
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TBAF  Tetra-n-butylammonium fluoride 
THF  Tetrahydrofuran 
THP  Tetrahydropyran 
TOCSY TOtal Correlation SpectroscopY 
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1. Aim of the project 
The lithiation-halogenation methodology for the functionalization of purine 8-position has 
been explored by our group
1-3
 and others
4-12
 (Scheme 1).  
 
Scheme 1. Overview of previous work done.
1,2
  
Studies have shown successful results in synthezising 8-halopurines 2a-b from 6-chloro-9-
substituted purines 1a-b by employing LDA as a base followed by trapping with an 
electrophillic agent giving excellent yields (Scheme 1). 
1
          
Also, studies done on the 9-benzylpurines 1c have shown that excellent yields of compound 
2c can be obtained when the benzyl group carried an alkoxy or alkyl group in the ortho or 
para position (Scheme 1). 
2
 
In continuation with this, the present work is mainly aimed towards the investigation of the 
scope and limitations of C-8 functionalization of various 9-alkyl purines 4. Additionally, N-
alkylation of purines 3 under different conditions has also been studied in an attempt to 
identify the most efficient method(s) for the synthesis of each particular substrate (Scheme 2).  
10 
 
 
Scheme 2. Reagents and conditions: (a) Base, alkylhalide, r.t., 1.5 h- 20 h; (b) LDA, 
Electrophillic halogen source, -78ºC, various length of time. 
 
2. Introduction 
2.1 General 
Purines are heterocyclic aromatic compounds, consisting of a pyrimidine ring (7) fused to an 
imidazole ring (8) (Figure 1).
13
 The name purine originates from the Latin word purum (pure) 
and uricum (urine). The name of this heterocycle was given by Emil Fischer as it was first 
synthesized from uric acid.
14
  
 
Figure 1. The purine ring (6) and the accepted numbering system, pyrimidine (7) and 
imidazole (8)  
Owing to their large abundance in natural products and biomolecules, the purine scaffold has 
received an enormous interest among biologists and chemists. The most important purine 
containing biomacromolecules are DNA and RNA. 
 
2.2 Biological significance / role / importance of naturally occurring purines 
2.2.1 Genetic material 
Purines and pyrimidines are two of the building blocks of nucleic acids. Only two purines and 
three pyrimidines occur widely in nucleic acids. The purine bases consist of adenine (9) and 
11 
 
guanine (10). The pyrimidine bases consist of cytosine (11), thymine (12) and uracil (13). 
(Figure 2)  
 
Figure 2. Structure of purines and pyrimidines in DNA/RNA 
Two nucleotides on opposite complementary DNA or RNA strands that are connected 
via hydrogen bonds (hashed bonds) are called a base pair. The wavy bonds indicate the 
attachments on the nucleic acid chain. In DNA base pairing, adenine (A) forms a base pair 
with thymine (T) and guanine (G) forms a base pair with cytosine (C). In RNA, thymine (T) is 
replaced by uracil (U) (Figure 3).
15
  
 
 
Figure 3. A-T (14) and G-C (15)base pairing.
15
  
 
2.2.2 Hormones and Neurotransmitters 
Cytokinines are a class of plant growth substances (plant hormones) that promote cell 
division, or cytokinesis, in plant roots and shoots. Zeatin (16) was the first cytokinine isolated 
from corn (zea mays) (Figure 4).
16
 Cytokinines are normally adenine derivatives substituted 
on the N6 position. Zeatin (16) has also been reported to have anti cancer properties both in 
vitro and in vivo. Additionally, it is also reported to have  several in vitro anti-aging effects on 
human skin fibroblasts.
17
  
12 
 
 
Neurotransmitters are endogenous chemicals which transmit signals from a neuron to a target 
cell across a synapse. Adenosine 17 (Figure 4)is an inhibitory neurotransmitter, believed to 
play a role in promoting sleep and suppressing arousal, with levels increasing with each hour 
an organism is awake. Adenosine is a nucleoside composed of a molecule of adenine attached 
to a ribose sugar molecule. Adenosine also plays an important role in biochemical processes, 
such as energy transfer—as adenosine triphosphate (ATP) and adenosine diphosphate (ADP) 
(Figure 4)—as well as in signal transduction as cyclic adenosine monophosphate, cAMP.18 
 
Figure 4. Structures of zeatin (16) and adenosine (17) 
 
2.2.3 Energy transfer 
ATP (18) is among the most important biomolecules next to DNA/RNA. As far as known, all 
organisms from the simplest bacteria to humans use ATP (Figure 5) as its primary energy 
currency. ATP also plays a critical role in the transport of macromolecules across cell 
membranes, e.g. exocytosis and endocytosis. ATP consists of adenosine and three phosphate 
groups (triphosphate). Energy is liberated from the ATP molecule to do work in the cell by a 
reaction that removes one of the phosphate-oxygen groups, leaving adenosine diphosphate 
(ADP). When the ATP is hydrolyzed to ADP, the ATP is said to be spent. Then the ADP is 
immediately recycled in the mitochondria where it is recharged and comes out again as 
ATP.
19
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Figure 5. Structures of ATP (18) and ADP (19) 
 
This central biological importance together with medicinal chemists’ search for anti-tumour 
and anti-viral (particularly anti-AIDS) agents has resulted in a rapid expansion of purine 
chemistry in recent years.  
 
2.3 Physicochemical properties of purines 
2.3.1 Tautomerism 
Purine can exist in four NH-tautomeric forms depending on the site of attachment of the 
proton at the ring nitrogens (Scheme 3).  The 1H- and 3H-tautomers (6a) and (6b) are much 
less stable than the 7H- and 9H- tautomers (6c) and (6). Only the latter are known to exist in 
concentrated aqueous solution.
20,21
 In the solid state, purines exist as the 7H-tautomer (6c).
20,21
  
 
 
Scheme 3. Purine tautomers 
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2.3.2 Acidity 
The NH proton in purine is acidic and can easily be abstracted by a base, although this 
property is useful in N-alkylation of purines, it is necessary to protect the N9- or N7- positions 
before other acidic protons e.g. H-8 and H-2 can be removed/abstracted (Scheme 4).
22
  
 
 
Scheme 4. Purinyl anion 
Electron-withdrawing groups decrease basicity while electron-donating groups increase 
basicity of purines.
13
 Some pKa values are shown in Table 1.
23,24
 
 Table 1. pKa values of amino- and chloro-substituted purines.
23,24
 
Purine pKa 
Purine-6-amine 2.39 
Purine-2,6-diamine 5.09 
Purine-2,6,8-triamine 6.23 
6-Chloropurine 0.45 
2,6-Dichloropurine -1.16 
2,6,8-Trichloropurine -3.1 
 
2.4 Purine Synthesis 
Purine (6) itself does not occur naturally. The first synthesis of purine was demonstrated by 
Emil Fischer in 1899 from uric acid (Scheme 5). Uric acid (20) was reacted with PCl5 giving 
15 
 
2,6,8-trichloropurine (21), which then was converted with HI and PH4I giving 2,6-
diiodopurine (22). The product was reduced to purine (6) using zinc.
14
 
 
Scheme 5. Synthesis of purine (6) from uric acid (20). Reagents and conditions: (a) PCl5 (b) 
HI/PH4I (c) Zn.
14
 
Since then, a variety of routes towards purine 6 have been published in the literature (Scheme 
6).
25,26
  Purine (6) can be formed in one-step by heating formamide (23) for 28 hours, this 
gave a yield of 71%.
25
  Purine (6) can also be formed in two-steps via reduction of the 
hydrazine 26 and 27 that gave a yield of 95% (Scheme 6).
26
 
 
Scheme 6. Synthesis of purine. Reagents and conditions: (a) heated at 170-190 ºC for 28 h
25
; 
(b) NH2NH2∙H2O, EtOH, reflux, 30 min; (c) NaOH, H2O, reflux, 12 h.
26
   
 
With the discovery of purine scaffolds in diverse biomolecules, substantial efforts have been 
made towards functionalization of purines and its analogs. 
One of the most widely explored reactions of functionalization of purines is the N-alkylation. 
 
16 
 
2.5 N-alkylation of purines 
N-alkylpurines are not only important from the biological point of view, but they also offer an 
additional advantage of masking or removing the acidic N-H proton in the synthetic 
sequences. 
A variety of methods have been developed for the N-alkylation of purines. The reactions are 
strongly dependant on the substituent in the C-6 position,
27
 the choice of base
22
 and the 
concentration of the reaction mixture.
13
 The ratio of N9- to N7-alkylation product increases 
with the size of the substituent in the C-6 position.
27
 N3-alkylated products are formed under 
neutral conditions,
28 
but N9- and N7-alkylated products are observed under basic 
conditions.
22,28
 As a result of the alkylation of purines, the N9-alkylated products are 
predominant in most of the cases.  
 
2.5.1 Base-induced coupling 
Base-induced coupling is the most known general method of the alkylation reactions. It 
consist of generating a purinyl anion in the presence of a base such as alkali metal carbonates 
(K2CO3, Cs2CO3), or hydride (NaH) in a polar solvent.  
Zhang L. et al have previously reported the alkylation reactions (Scheme 7) in high yield (79-
95%). 
 
Scheme 7. Base-induced coupling reaction. Reactants and conditions: Cs2CO3, alkyl halide, 
r.t. or 50 ˚C, 16h. 28 
17 
 
2.5.2 Mitsunobu Reaction 
A brief desciption of the Mitsunobu reaction is decribed here for the purpose of making a 
comparison with the alkylation method described in Section 2.5.3. 
The Mitsunobu reaction
29
 is a versatile reaction for the functionalization of a range of 
alcohols.
30-38
 A general N-alkylation procedure for 6-chloropurines have been developed 
using various alcohols and diethylazodicarboxylate (DEAD) (Scheme 8).
31,34
 The N9- 
alkylated products are formed in high yields compared to the N7-alkylated product. However, 
this procedure is limited by the removal of triphenylphosphine oxide by-product, making it 
unsuitable for large scale syntheses.
32
 
 
Scheme 8. Mitsunobu reaction gave yields of compounds 30 and 31.
34
 
 
2.5.3 Phase-transfer catalysis 
N-alkylation of 6-substituted purines employing various types of phase-transfer catalyst has 
proven to be a convenient and efficient method due to its short reaction time, simple work up 
and high yields. These reactions are mainly run in aqueous media and favor substitution in the 
N9-position. Aliquat 336 and TBAF are  quaternary ammonium salts typically employed in 
phase transfer catalyzed alkylations.
39
   
Previously, this kind of alkylation relied on methods done under Mitsunobu condition 
(Scheme 8) with a variety of alcohols
36
 or a strong basic condition (NaH, K2CO3) with a 
variety of alkyl and benzyl halides.
40,41
  These reactions require long reaction times (10-48 h), 
low temperatures for Mitsunobu or elevated temperatures for basic conditions, and an inert 
atmosphere due to the sensitivity of the reagents in order to obtain higher yields and a better 
N9-  to N7-ratio of the products. Thus, phase transfer catalysis offers several advantages over 
Mitsunobu conditions in the N-alkylation of purines. 
18 
 
A study has been done employing TBAF facilitated alkylation of purines and  pyrimidines.
42
 
The reactions were conducted in 1 hour and gave excellent yields of 85-99%.
42
 The N9-
methylation of adenine (9) gave an excellent yield of compound 32 95%. (Scheme 9) 
 
 
Scheme 9. TBAF facilitated methylation.
42
 
 
Another study was done and examined the effect of TBAF in the N9-purine scaffolds. It was 
reported that TBAF at room temperature remarkably accelerates the N9-alkylation of the 
purine ring with a variety of alkyl halides.
43
 An alkylation method that could run without dry 
conditions was crucial in this study for applications on microtiter plates.  (Figure 6) 
 
 
Figure 6. Microtiterplate (http://www.gtsci.com/) 
2,6-dichloropurine (33a) was treated with TBAF followed by addition of R-X using THF as 
the solvent (Scheme 10). The ratio of N9/N7 was determined by LC-MS, which showed that 
the N9-isomer was the major isomer formed. The isolated yields were excellent (90-95%). 
When 2-amino-6-chloropurine (33b) and 1-bromodecane (Table 2, entry 5) was reacted under 
the same conditions, a longer conversion time was needed. This reaction gave a lower yield 
but good selectivity.
43
 
19 
 
 
Scheme 10. Reagents and conditions: TBAF (2 eq), R-X (2 eq), THF, time given in Table 2 
(entries 1-5).
43
 
 
2-chloro-6-naphthylpurine (36) was treated with TBAF and addition of R-X, using THF as the 
solvent (Table 2, entries 6-8). In entries 9 and 10 (Table 2) were heated to 60˚C. The 
selectivity was excellent even though some of yields were lower (Scheme 11).
43
 
 
 
Scheme 11. TBAF (2 eq), R-X (2 eq), THF, time given in Table 2.
43
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Table 2. TBAF assisted N9-alkylation  of 33a-b and 36.
43
 
entry s.m. R-X N9/N7 ratio t Yield (%) 
1 33a 
 
70/30 10 min 95 
2 33a  70/30 10 min 96 
3 33a 
 
86/16 10 min 98 
4 33b 
 
70/30 10 min 90 
5 33b  95/5 2 h 85 
6 36 
 
98/2 10min  97 
7 36 
 
99/1 10min 95 
8 36 
 
98/2 10min 95 
9 36 
 
98/2 3h 70 
10 36 
 
98/2 12h 50 
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2.6 8-Halopurines 
8-Halopurines and N9-substituted 8-halopurines are versatile intermediates that provide 
access to diversely substituted 8-susbstituted purine derivatives.
44
 Some of the interesting 
bioactive 8-susbtituted purines synthesized by Zhang et al via 8-halopurines are exemplified 
in Scheme 12.  
 
Scheme 12. Bioactive purine (43) synthesized from 8-halopurine (39).
28
 Reagents and 
conditions: (a) t-BuOK, DMF, 130ºC; (b) NH3∙MeOH, r.t., overnight; (c) MsCl, Et3N, DMF, 
0ºC to r.t., 10 min; (d) NH3, MeOH, r.t., overnight. 
22 
 
2.7 Synthetic utility of 8-halopurines 
2.7.1 Hydrolysis 
 
8-Bromopurines can be hydrolysed into its oxo-analogs (Scheme 13). It was reported that 
compound  45 was formed in 58% from the hydrolysis of 8-halopurine 44.
45
 
 
Scheme 13. Reagents and conditions: 0.1M aq NaOH in THF (2 eq), 0˚C.45 
 
2.7.2 Coupling in the C-8 position examples 
8-Halopurines are generally suitable for undergoing coupling reactions, namely C-N and C-C 
coupling. Some examples are given below (Section 2.7.2.1 and section 2.7.2.2). 
 
2.7.2.1 Hsp90 inhibitors 
Heat shock protein 90 (Hsp90) maintains proper folding conformation of proteins. The 
inhibition of Hsp90 results in misfolded proteins that are rapidly degraded by the proteasome. 
In this manner, Hsp90 has potententially theraputic utility in treating a multitude of diseases 
including cancer.
46
 
Compound 47 is a general structure for the 23 differently coupled analogues synthesized 
reported by Zhang et al. in good yields, 65-86% (Scheme 14).
28
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Scheme 14. Hsp90 inhibitors (47)
28
 
 
2.7.2.2 AA2AR antagonists 
Adenosine A2A Receptor (AA2AR) is linked to the stimulation of the enzyme adenylyl cylase. 
47
 AA2AR are potential alternative approach for the treatment of Parkinson’s disease.
48-50
 
 
Scheme 15 illustrates the most interesting AA2AR antagonists synthesized by Volpini et al.
51
 
AA2AR antagonists’ affinity and selectivity may provide a new option suitable for in vivo 
studies in rat models of Parkinson’s disease. Compound 49 and 50 was obtained in excellent 
yields of 77-80 %. Compound 51 gave 13 % yield (Scheme 15). 
24 
 
 
Scheme 15. AA2AR antagonists synthesized from compound 48. (a) HCOOH or NaOH, ROH, 
80ºC, 3 h; (b) (nBu)3Sn-furan, (PPh3)PdCl2, THF, reflux, 24 h; (c)CF3COONa, NMP, 80ºC, 2 
h.
51
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2.8 Synthesis of 9-substituted 8-halopurines: 
8-Halopurines can be synthesised in a variety of routes from compound 3.  Two routes are 
illustrated in Scheme 16. 
 
Scheme 16. Two general routes for synthesizing 9-substituted 8-halopurines 5 from 
compound 3 
Route 1: (a) Base, R-X in DMF or THF; (b) i. LDA in THF ii. Electrophile in THF or NBS or 
NCS or Br2 or I2 in DMF 
 
Route 2: (c) Br2 in buffered aquoeus media or NBS/FeCl3 in CHCl3; (d) Base, R-X in DMF 
 
2.8.1 Route 1, N-Alkylation followed by Lithiation/Halogenation  
The first route (Scheme 16) is a generalized route for the synthesis of 8-halo-N9-alkyl purines, 
from N9-alkylated purines. Essentially N9-alkylated purines can be halogenated at C-8 
position by trapping a purinyl anion (derived by a reaction with LDA) with an electrophilic 
halogen source in excellent yields. 
1,2,4-12
 Alternatively, N9-alkyl purines can be subjected to 
halogenations using bromine or N-halosuccinimides. The use of NBS as a bromine source for 
26 
 
the bromination of compound 4 often result in low and poorly reproducible yield of the 
desired compound 5.
52
 
 
2.8.2 Route 2, The Bromination followed by N-Alkylation Reaction 
The alkylation – halogenation sequence is reversed in this route. The N-unsubstituted purines 
can be brominated using molecular bromine or NBS and resulting bromide 43 can be 
subjected to N-alkylation. The direct bromination of the C-8 position of adenine (9) using Br2 
is common, giving 8-bromoadenine (53) in a yield of 70% (Scheme 17).
53,54
  
 
Scheme 17. Reagents and conditions: (a) Br2, DMF, r.t., overnight;
53
 (b) Br2, DMF, 70 ºC, 2 
h.
54
 
The bromination of adenine (9) may be convienient, however, the N-alkylation of 8-
bromoadenine (53) lead to the formation of N3 and N9-alkylated products.
54-58
  A reported 
example of the alkylation of 8-bromoadenine (53) is shown below (Scheme 18).
54
 The 
reaction gave a 1 : 1.3 ratio of the N9 : N3-alkylated products; formed majorly N3-alkylated 
product.  
 
Scheme 18. Reagents and conditions: NaH, 4-fluorobenzyl bromide, DMF, 70ºC, 2 h.
54
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2.8.3 The Project Route 
Route 1 employing LDA has been a method of choice for the synthesis of N9-alkyl 8- 
halopurines in our group as the desired products are the N9-alkylated analogs.
1-3
  
A variety of electrophiles were used. 1,2-dibromo-1,1,2,2-tetrachloroethane (56) and 
cyanogenbromide (57) were employed as electrophilic bromine source. 
1-3
 Perchloroethane 
(58) was employed as electrophilic chlorine source.
1,3
 (Figure 7) 
 
Figure 7. Electrophile sources. 
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3. Overview of Lithiation Reactions 
3.1 LDA 
Lithium diisopropylamide, LDA (62) in THF is the most frequently used base for 
deprotonating weakly acidic protons. LDA is a non-nucleophillic base. LDA is formed by 
adding n-BuLi (59) dropwise to diisopropylamine (60) in THF at -78˚C under inert 
conditions
59
(Scheme 19). 
 
Scheme 19. Formation of LDA. 
 
LDA was used beacause commonly used strong bases such as hydroxides e.g. KOH, NaOH 
will lead to nucleophillic substitution reactions instead of deprotonation. The OH
-
 of the 
hydroxides are highly nucleophillic and will displace halides and other leaving groups giving 
the hydrolysed compound. An example of a reported reaction using NaOH as a base is shown 
below (Scheme 20).
60
 
 
Scheme 20. Reagents and conditions: NaOH, dioxane/H2O, reflux.
60
 
 
3.2 LDA vs. Alkyllithiums 
LDA act only by deprotonation. Alkyllithiums such as n-butyllithium and t-butyllithium can 
act as bases or take part in halogen exchange. When using alkyllithiums, exchange is favoured 
over deprotonation by the use of lower temperatures (Scheme 21).
61
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Scheme 21. Lithiation employing LDA and t-BuLi.
61
 
 
3.3 Electrophiles  
A variety of electrophiles can be used to trap 8-purinyl anions. It was demonstrated by 
Gudmundsson et al that compound 68 can be isolated in moderate yields for the methylated 
compound (69a) and excellent yields for the halogenated compounds (69b-d)
52
 (Scheme 22). 
 
 
Scheme 22. Reagents and conditions: i. LDA in THF, -78˚C, 30 min, ii. electrophile (See 
Table 3), THF, -78 ºC, 3-4 h.
52
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Table 3. Electrophiles used and isolated yields.
52
 
Entry Electrophile, eq X Yield, % 
1 CH3I, 2.5 CH3 69a, 48 
2 C2Cl6, 3.0 Cl 69b, 86 
3 Br2, 2.6 Br 69c, 81 
4 I2, 2.6 I 69d, 73 
 
 
3.4 Earlier Reports on Formation of Dimers and Aldehyde by-products  
By-products may form in lithiation-bromination reactions such as symmetrical- (72), 
assymetrical dimers (74) (Figure 8)  and aldehydes (73) (Scheme 23)
2
.  
 
Scheme 23. Lithiation/Bromination of 8-bromo-N-benzylpurines. Reactants and conditions: i. 
LDA in THF, ii. Br2C2Cl4.
2
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Figure 8. Asymmetrical dimer.
2
 
 
It is unusual for dimers to form in using the method depicted in Scheme 24 . Dimers have 
been reported formed by employing Negishi cross-coupling reaction with a Pd-catalyst
62
 
(Scheme 24). 
 
Scheme 24. Dimerization formed from 6,8-dihalopurines by Negishi cross-coupling.
62
 
 
3.4.1 Mechanism for Purine Dimerization 
Two mechanisms have been proposed for the formation of purine dimers (Scheme 24).
2
 
The lithiation (step a) in Scheme 25 is common for both routes of dimer (82) formation. 
In route 1, the lithiated species (79) reacts with the starting material (78) forming compound 
80. The ionic species (80) formed is oxidised into compound 82 during work up. 
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In route 2, the lithiated species (79) is trapped with bromine electrophile forming the C-8 
brominated compound 81 (Scheme 25). The untrapped lithiated species (79) continues to react 
with the formed compound 81, which now has a better leaving group in the C-8 position 
forming a dimer. 
 Route 2 is proposed to be the most likely pathway of the two routes for the dimerization as 
when the bromine electrophile was added over 1 minute, only product was observed. 
However, when the bromine electrophile was added over 10 minutes, the ratio of compounds 
82:78 observed were 5:1.  
 
Scheme 25. Proposed mechanism of purine dimerization.
2
 Reagents and conditions: (a) LDA, 
(b) Br2C2Cl4, (c) oxidation or oxidation/protonation during work up. 
 
3.4.2 Mechanism for Aldehyde Formation 
There are various possibilities of the formation of the aldehyde by-product 88. In compound 
78, the two aromatic rings which bond to the NCH2 pulls the electron density away from the 
carbon on this position causing this position to be electron deficient enough for deprotonation 
using strong base LDA. This forms the carbanion (83). The carbanion (83) can react with 
oxygen forming the hydroxylated compound 84. Alternatively, the carbanion (83) is trapped 
with bromine electrophile forming compound 86. The bromide is now a good leaving group 
and may undergo nucleophillic substitution with water forming a hemiaminal (84) that readily 
oxidises into a ketone (87). Finally, debenzylation of compound 87 or 84 giving the 
debenzylated compound (85) and aldehyde by-product (89)
2
 (Scheme 26). 
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Scheme 26. Proposed mechanism of the formation of the aldehyde by-products.
2
 
 
3.5 Formation of other by-products 
3.5.1 Halogen-exchange by-products 
Organolithiums can react by halogen-metal exchange as mentioned in section 3.2
61
. n-BuLi 
can therefore form a halogen-metal complex (90) from the desired compound 89, followed by 
trapping with an electrophile (E
+
) giving by-product 92 (Scheme 27).  
 
Scheme 27. Possible mechanism for the formation of halogen-exchange compound 92. 
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3.5.2 Double-bond Migration 
9-Allylpurines (93) have been observed to undergo double-bond migration in the allyl group 
(Scheme 27). According to the pKa values in Table 4 and Table 5, protons of the allyl group 
can undergo deprotonation in the presence of n-BuLi, but not usually LDA. The pKa values 
for the methyl and ethyl groups (Table 4) are much higher than that of LDA (Table 5), a 
possible explanation for why they are not deprotonated during lithiation reactions. 
 
Table 4. Hydrocarbon pKa values                            Table 5. Base pKa values 
Hydrocarbon pKa
63
  Base pKa 
CH3-H 48  n-BuLi ~50
64,65
 
CH3CH2-H 51  LDA 36
66
 
CH2=CH-CH2-H 38    
 
However, the allyl group is connected to the purine ring. This might cause the lowering of 
pKa value of the allyl group. Furthermore, deprotonation of the proton on the allyl chain 
results in a conjugated system (94) to form which is more stable (Scheme 28). 
 
Scheme 28. Mechanism for Double-bond migration of allyl purine. 
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4. Results and Discussion 
The discussion is organized into two parts. The first part is about the synthesis and 
characterisation of starting materials (Scheme 29, part a). The second is about the 
lithiation/halogenation reactions (Scheme 29, part b).  
 
Scheme 29. Two steps of the project: (a) N-alkylation, (b) Lithiation-halogenation 
 
All successful isolated compounds made were fully characterised and NMR signals were 
assigned with 1D (
1
H and 
13
C) and 2D (HMQC and HMBC) NMR spectra. 
1
H NMR spectra of crude products were analysed to determine the ratio of compounds 
formed.   
Coupling constant (J) in Hz were calculated for identifying E or Z-isomers. 
4.1 N-alkylation 
A general N-alkylation reaction is illustrated in Scheme 30.  
 
Scheme 30. N-alkylation mechanism. 
5 
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4.1.1 Synthesis of 6-chloro-9-methyl-9H-purine (97a) and 6-chloro-7-methyl-7H-purine 
(97b) 
 
Several procedures have been reported for the synthesis of compound 97a (Scheme 31). The 
method chosen (Scheme 31, method e) for the synthesis of compound 97a was the most 
practical method because of its simplicity and high yields. 
 
Method (e) did not require neutralisation at the end of the reaction, because NaH was not used 
(Scheme 31, method a). The use DMSO as a solvent because DMSO has a high boiling point 
(190ºC) was avoided (Scheme 30, method b). DMF has a boiling point of 150ºC, which is 
lower than that of DMSO. A sealed tube was not needed (Scheme 31, method c). The reaction 
done under Mitsunobu conditions (Scheme 31, method d) was not attempted, as the removal 
of triphenylphosphine oxide formed from the oxidation of triphenylphosphine is reported 
difficult by chromatography.
32
 
 
Using method (e) 6-Chloropurine 29 was N-alkylated with iodomethane in the presence of 
potassium carbonate. DMF was the solvent. According to the 
1
H NMR spectrum of the crude 
product, the N-9 and N-7 methylated isomers were formed in a ratio of 80:20. Products 97a 
and 97b were isolated in yields of 78 % and 19 % respectively by flash chromatography 
(Scheme 31). Product 97a being the desired compound for use in a further step. 
 
 
Scheme 31. Reactions and conditions: (a) i. NaH, ii. MeI, DMF, r.t. 16h
58
; (b) K2CO3, MeI, 
DMSO, r.t., 24 h
67
; (c) K2CO3, MeI, DMSO, sealed tube, 55ºC, 30 min; (d) PPh3, DIAD, 
MeOH, r.t., 1 h
68
; (e) K2CO3, MeI, DMF, r.t., 16 h 
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Compound 97a is known in literature.
67
 The unambiguous determination of the regiochemical 
outcome of the reaction was of particular importance. In the HMBC spectrum, diagnostic 
long-range couplings from both H-2 and CH3 to C-4 established the N-9 regioisomer as the 
correct one. Correlations to C-5 were not observed. (Table 6) 
 
Table 6. Selected correlation from long range HMBC spectrum for the N9- isomer (97a).  
X = coupling between carbon and hydrogen. 
 
 
 
 H-2 H-8 CH3 
C-4 X X X 
C-5  X  
C-6 X   
C-8   X 
CH3  X  
 
In contrary to compound 61a, compound 61b was determined as the N7- regioisomer. 
Correlations of CH3 to C-5 and C-8 confirms that to be correct indeed. (Table 7) 
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Table 7. Selected correlation from long range HMBC spectrum for the N7- isomer (97b).  
X = coupling between carbon and hydrogen. 
 
 
 
 H-2 H-8 CH3 
C-4 X X  
C-5   X 
C-6 X   
C-8   X 
CH3  X  
 
 
4.1.2 Synthesis of 9-allyl-6-chloro-9H-purine (98a) and 7-allyl-6-chloro-7H-purine (98b) 
 
Two methods were found for the N-allylation of 6-chloropurine 29. (Scheme 32) Method (a) was 
more tedious and method (b) was practical and effective. So method (b) was attempted for the  
synthesis of compounds 98a and 98b. 
 
6-Chloropurine 29 was N-alkylated with allyl bromide in the presence of potassium carbonate. 
DMF was the solvent (Scheme 32).69 According to the 1H NMR spectrum of the crude product, 
the N-9 and N-7 allylated isomers were formed in a ratio of 73:27.  Products 98a and 98b were 
isolated in 59 % and 20 % yields, respectively by flash chromatography.  
 
Scheme 32. (a) i. NaH, THF or DMF, 60ºC, 45 min, ii. (Ph2P)2-ferrocene, Pd(PPh3)4, allyl 
acetate, THF or DMF, 60ºC, 10 h
70
; (b) i. K2CO3, DMF, r.t., 20 min, ii. allyl bromide, 20 h.
69
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The determination of the N-9 (Table 8) and N-7 isomers (Table 9) were done in a fashion 
similar to what has been done for the products formed (compounds 98a and 98b) in the 
preceding reaction described (Section 4.1.1, Scheme 31). Additionally, the 
1
H NMR values of 
compounds 98a and 98b is in good agreement with values reported in literature.
69,71,72 
Table 8. Selected correlation from long range HMBC spectrum for the N-9 isomer (98a).  
X = coupling between carbon and hydrogen. 
 
 
 
 H-2 H-8 CH2 
C-4 X X X 
C-5  X  
C-6 X   
C-8   X 
CH2  X  
 
 
Table 9. Selected correlation from long range HMBC spectrum for the N-7 isomer (98b).  
X = coupling between carbon and hydrogen. 
 
 
 
 H-2 H-8 CH2 
C-4 X X  
C-5   X 
C-6 X   
C-8   X 
CH2  X  
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4.1.3 Synthesis of 9-methyl-9H-purin-6-amine (99a) 
The synthesis of compound 99a (Scheme 33) has been performed before employing method (a) 
which reported yields of 69% of N9-methylated adenine 99a and 23% of the N-7 methylated 
adenine 99b. This procedure required tedious purification by flash chromatography to isolate 
compound 99a.73 This method was not attempted to avoid the complicated purification.  
Method (b) was employed; the resulting reaction mixture was dissolved in methanol, filtered and 
yielded solely the N9- isomer (99a) in 75% yield. 
 
Scheme 33. Reagents and reactants: (a) K2CO3, methyl halide, DMF, r.t., 2 h.
73
; (b) TBAF,  
methyl iodide, THF, 1.5 h.
42
                                                 
Tetra-n-butylammonium fluoride (TBAF) is a very bulky molecule (Scheme 34); the 
deprotonation in the N7-position of adenine (9) is hindered by the presence of the amine 
group in the C-6 position. This is probably the reason for the alkylation exclusively in the N9-
position. 
 
Scheme 34. Possible mechanism for yielding solely the N9-alkylated compound (99a)  
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The 
1
H NMR shift values are in good agreement with literature.
73
 Additionally, the structure 
elucidation of compound 99a was done and verified as the N9-methylated compound (Table 
10). The presence of correlation from CH3 to C-4 and C-8 in HMBC observation confirms the 
identity of compound 99a. 
Table 10. Selected correlation from long range HMBC spectrum for the N9- isomer (99a).  
X = coupling between carbon and hydrogen. 
 
 
 
 H-2 H-8 CH3 
C-4 X X X 
C-5  X  
C-6 X   
C-8   X 
CH3  X  
 
 
4.1.4 Synthesis of 9-ethyl-9H-purin-6-amine (101a) and N,9-diethyl-9H-purin-6-amine 
(101c) 
The TBAF reaction was convenient for forming the N9-methylated compound 99a, so method 
(a) was also attempted for the synthesis of the N9-ethylated compound 101a (Scheme 35). 
Unfortunately, both TBAF and the product, compound 101a were soluble in methanol, so the 
resulting mixture was evaporated in vacuo and purified by repeated flash chromatography. 
This reaction gave compound 101a in a yield of 84%, but is considered ineffective. 
TBAF is not UV active, which made it impossible to gauge when it elutes from the flash 
column. Furthermore, the product (101a) is highly polar. An attempt to purify by 
recrystallization failed. It has been reported that TBAF dissolves in most organic solvents, 
both polar and non-polar.
74-81
 The fact that TBAF dissolves in most oragnic solvents was 
confimed by collecting the ―blank‖ chromatography fractions (DCM, DCM/Acetone, and 
Acetone) in several batches which were tested and easily identified by 
1
H NMR. Four very 
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distinct NMR signals of the butyl chain were identified. The inconvenient purification for the 
isolation of pure compound 101a lead to the the search for another more advantageous 
procedure. 
The synthesis of compound 101a (Scheme 35) has been reported using method (b) which 
reported yields of 59% for compound 101a and 10% for compound 101b.
73
 This procedure 
was not attempted as another produre (method c) which reported formation of exclusively the 
N9-isomer in high yields was more appealing. 
Method (c) was attempted at room temperature. At the end of the reaction time, the reaction 
mixture was quenched with water; according to the literature,
28
 a precipitate was expected to 
form followed by filtration, unfortunately no precipitate was formed, so the mixture was 
evaporated in vacuo and was purified by flash chromatography. Only the N9-isomer (101a) in 
83 % was isolated in this case.  
Method (c) was also attempted at 50ºC in anticipation to achieve the 91% yield of compound 
101a as was reported in literature.
28
 Besides formation of compound 101a, a dialkylated by-
product 101c was also formed. Compound 101a was isolated in 86% and Copound 101c was 
isolated in 2%. 
Method (c) at room temperature was the most effective of the three methods depicted in 
Scheme 35.  
 
Scheme 35. Reagents and reactants: (a) TBAF,  iodoethane, THF, 5 h.
42
; (b) K2CO3, 
ethylhalide, DMF, r.t., 6 h.
73
; (c) Cs2CO3, iodoethane, DMF, r.t. or 50ºC, 16 h.
28
 
 
Heating the reaction mixture in method (c) could have made it possible for adenine (9) to 
exist in another tautomer 102 (Scheme 36).  
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Scheme 36. Mechanism for the formation of dialkylated compound 101c. 
Compound 101a was identified by HMQC and HMBC. The correlations of CH2 to C-4 and C-
8 were crucial in determining the position of the ethyl-group. (Table 11) 
Table 11. Selected correlation from long range HMBC spectrum for the 9-Ethyl-9H-purin-6-
amine (101a). X = coupling between carbon and hydrogen. 
 
 
 
 H-2 H-8 CH2 
C-4 X X X 
C-5  X  
C-6 X   
C-8   X 
CH2  X  
 
Compound 101c is less polar than the desired compound (101a) and eluted first from the flash 
column during purification. MS revealed m/z 192, different compound than compound 101a 
which has a m/z 163. Compound 101c should be a compound that contains two ethyl groups.  
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The possible isomers of diethyladenine are illustrated in Figure 9. The NOESY spectrum did 
not show correlations for the ethyl groups, so structure 101e and structure 101f were 
eliminated as candidates of the by-product.  
 
Figure 9. Diethyladenine isomers. 
 
The N6-CH2 to C-6 correlation is missing in our HMBC spectrum. (Table 12) The N6-CH2 
peak in the 
1
H NMR would naturally be expected as a multiplet but instead a broad singlet 
was observed.  
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Table 12. Selected correlation from long range HMBC spectrum for N,9-diethyl-9H-purin-6-
amine (101c).  X = coupling between carbon and hydrogen. 
 
 
 H-2 H-8 N9-CH2 N6-CH2 
C-4 X X X  
C-5  X   
C-6 X   missing 
C-8   X  
N9-CH2  X   
 
The structure of compound 101d have been reported in literature with the assignment of the 
N6-CH2 peak as a quartet
82
 and this does not match with our 
1
H NMR observation. The 
different 
1
H NMR values recorded in literature
82
 is an indication for our belief that our by-
product is not the structure of compound 101d. The observed NOESY correlations for the N6-
alkylated structure (Figure 10, curly arrow) confirms the structure of compound 101c.  
 
Figure 10. Characteristic NOESY correlation for compound 101c. 
 
4.1.5 Synthesis of 9-allyl-9H-purin-6-amine (104a) and 3-allyl-3H-purin-6-amine (104c) 
There were two procedures (Scheme 37) found in the synthesis of 9-allyl-9H-purin-6-amine 
(104a). Method (a) was done instead of method (b) for three reasons. First, the procedure in 
method (b) did not state the reaction temperature. Secondly, the thick and sticky consistency 
of aliquat 336 makes it difficult to weigh accurately. Thirdly, was reported that method (b) 
gives four products 104a, 104c-e. 
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Adenine (9) was treated with sodium hydride and allylated with allylbromide (Scheme 37).
72
 
The 
1
H NMR spectrum of the crude product revealed that 104a:104b:104c were formed in the 
ratio of 73:5:22. Compounds 104a and 104c were isolated in yields of 41% and 13% 
respectively, but 104b was not isolated. 
 
Scheme 37. Reagents and conditions: (a) NaH, allyl bromide, DMF, r.t., 2 h.
72
; (b) KOH, 
aliquat 336, allyl bromide, 10 min.
71
 
 
1
H NMR shifts for compound 104a is in good agreement with literature.
71
 Nevertheless, 2D 
NMR (HMQC and HMBC) was used to verify the structure of compound 104a. The 
correlations of –CH2 to C-4 and C-8 verifies that the allyl group is in the N9- position (Table 
13).  
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Table 13. Selected correlation from long range HMBC spectrum for 9-allyl-9H-purin-6-
amine (104a).  X = coupling between carbon and hydrogen. 
 
 
 
 
 H-2 H-8 CH2 
C-4 X X X 
C-5  X  
C-6 X   
C-8   X 
CH2  X  
 
We were able to recognize that compound 104b (Figure 11) was indeed formed in the reaction 
by careful analysis of the crude product 
1
H NMR and its comparison with the 1H NMR of 
reference sample of  compound 104b. 
 
Figure 11. Structure of 7-allyl-7H-purin-6-amine (104b) 
As the procedure reported by Thibon et al was followed (Scheme 37, method a), the N9- and 
N7-allylated adenine were the expected products.
72
 In the original report, characterisation was 
done on the N9-isomer but none on the N7-isomer. Nevertheless, the 
1
H NMR shift values for 
compound 104c are in good agreement with the literature
71
 that reported using method (b) 
(Scheme 37). The correlations observed in HMBC (Table 14) confirms the identity of 
compound 104c as the N3-allylated isomer. 
 
Table 14. Selected correlation from long range HMBC spectrum for 3-allyl-3H-purin-6-
amine (104c).  X = coupling between carbon and hydrogen. 
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 H-2 H-8 CH2 
C-2   X 
C-4 X X X 
C-5  X  
C-6 X   
CH2 X   
 
 
N3-alkylation occur under neutral conditions and N7/N9-alkylation occur under basic 
conditions.
22,27
 Despite using basic conditions, N3-alkylation occurred. This can be 
rationalised by the fact that the NH2 group’s bulky size (compared to Cl) which hinders 
alkylation in the N7-position. Additionally, the lone pair on the amino group can delocalize 
resulting in the activation of N3- position (Scheme 38). 
 
Scheme 38. Mechanism for N3-alkylation of adenine  
6-Chloropurine (29) on the other hand has a Cl group in the C-6 position. Cl group is electron 
withdrawing; this deactivates the ring, at the same time allowing the protons in the N9- and 
N7- position to be much more acidic, suitable for alkylation to occur in these positions. This is 
the reason why only N9- and N7-alkylation were observed in the case of 6-chloropurine (29). 
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4.2 Lithiation-halogenation reactions 
The proton in the C-8 position of purine is first deprotonated by a strong base, LDA, forming 
the purinyl-anion that can be trapped with an electrophile. When the C-8 position is is suitably 
functionalized in this manner, other groups can be introduced onto this position. (Scheme 39) 
   
 
Scheme 39. General lithiation-halogenation (bromination) reaction mechanism 
. 
4.2.1 Synthesis of 8-bromo-6-chloro-9-methyl-9H-purine (112) and 8-bromo-6-chloro-9-
ethyl-9H-purine (113) 
The general procedure for lithiation-halogenation
2
 was applied to compounds 97a and 111 
and it gave excellent yields of compounds 112 and 113 in 82% and 86% respectively (Scheme 
40). 
 
Scheme 40. Reagents and conditions: 1) LDA, 2) Br2C2Cl4, THF, -78ºC, 1 h. 
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4.2.2 Synthesis of 8-bromo-9-methyl-9H-purin-6-amine (114)  
Synthesis of 8-bromo-9-methyl-9H-purin-6-amine (114) via lithiation halogenation sequence 
proved to be challenging (Scheme 41). The major difficulty in this case was the low solubility 
of 99a in THF.  
 
Scheme 41. Reagents and conditions: 1) LDA, 2) Br2C2Cl4, THF, -78ºC-r.t., 2-16 h. 
 
Thus in an attempt to improve the solubility, the amount of THF per mmol of compound 99a 
was increased gradually from a typical volume of 4.0 mL to 30 mL in separate attempts, 
however no conversion was observed. (Table 15, entry 1-3). Upon further dilution of the 
reaction mixture, a moderate conversion was observed. (Entries 4 and 5). Additionally, the 
solubility issue was addressed by warming up the reaction mixture to ambient temperature 
over the period of 14 h, this approach however resulted in the formation of undesired side-
products and isolation of pure 114 was not possible.  
Yet another added difficulty was the contamination of the crude reaction mixtures with 
precipitated NH4Cl arising from the quenching agent i.e. sat. aq. NH4Cl. Presence of NH4Cl 
made it difficult to analyse the crude reaction mixtures with absolute clarity by NMR, thus the 
amount of quenching media was reduced to 2 mL (Table 15, entries 7-9). Finally, effect of 
very high dilution on the conversion was also investigated (entries 8-10).  
We envisioned that high dilution would result in better solubility and subsequently higher 
yields. However, in the initial attempts, (entries 8 and 9), it appeared that dilution was not 
affecting the isolated yields to a considerable extent. 
As an additional modification, the reaction mixture was repeatedly extracted (21 times), the 
1
H NMR of the crude product showed a moderate conversion but compound 114 was isolated 
in high yield. (entry 10) This discrepancy can be due to weighing errors. 
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Table 15.  Modifications in reaction conditions (See Scheme 41) 
Entry Vol. of THF 
(mL)/ mmol of 
64a 
Temp. (ºC), 
time 
Vol. of aq. NH4Cl 
for quenching 
Ratio of 
64a:71
a
 
Isolated 
yield of 71 
1 4 -78, 2 h 15 --
b
 --
b
 
2 6 -78, 2 h 15 --
b
 --
b
 
3 30 -78, 2 h 15 --
b
 --
b
 
4 60 -78, 2 h 15 56:44 32 % 
5 60 -78, 2 h 15 --
c
 41 % 
6 60 - 78, 2 h 
ambient, 14 h 
15 --
c
 --
d
 
7 60 -78, 2 h 2 62:38 30 % 
8 120 -78, 2 h 2 59:41 28 % 
9 120 -78, 2 h 2 55:45 33 % 
10 120 -78, 2 h 2 60:40 70 % 
a
 based on 
1
H NMR of the crude reaction mixture, 
b
 No conversion, 
c
 NMR inconclusive due 
to presence of NH4Cl and/or impurities, 
d
 impure 
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4.2.3 Synthesis of 8-bromo-9-ethyl-9H-purin-6-amine (115) 
Compound 101a also has low solubility in THF. (Scheme 42) At room temperature, one 
mmol compound of 101a was soluble in 30 mL of THF, but precipitated as white solid when 
cooled to -78ºC.  So, LDA was added to the stirring suspension of compound 101a. The 
reaction was run at this concentration, after quenching, the reaction mixture needed to be 
extracted 5 times instead of the usual 3 times as the product formed is quite hydrophilic. 
Compounds 115 and 116 were not separable by flash chromatography purification (Table 16, 
entry 1). The reaction was then repeated in the same manner, and produced similar isolated 
yield.(Table 16, entry 2) 
 
Scheme 42. Reagents and conditions: 1) LDA, 2) Br2C2Cl4, THF, -78ºC, 3 h. 
 
Table 16. Ratios formed and observed products 
Entry Ratio of 101a:115:116 
a
 Yield 
b
 
1 --
c
 115 68%, 116 8% 
2 13:77:10 115 70%, 116 10%  
a
 based on 
1
H NMR of the crude reaction mixture, 
b
 based on 
1
H NMR, 
c
 NMR inconclusive 
due to signal overlap. 
 
1
H NMR observation show two different H-2 shift values. MS (ESI) revealed a molecular 
weight corresponding to that of a bromoanalog, compound 115 and a chloroanalog compound 
116 was observed.  
Three possible mechanisms for explaining the chlorination of compound 101a are illustrated 
below (Schemes 43-45). 
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The first possibility for the formation of the 8-chloroanalog 116 is when the chlorine 
electrophile of 1,2-dibromo-1,1,2,2-tetrachloroethane is trapped by the 8-purinyl anion instead 
of the bromine electrophile (Scheme 43).  
 
Scheme 43. First possible mechanism for the formation of the 8-chloroanalog (116) if the Cl- 
electrophile was used instead of the Br-electrophile. 
 
The second posibility for the formation of the 8-chloroanalog 116 is if the chloride anion acts 
as a nucleophile. Since the bromide group in the C-8 position is a good leaving group, it can 
undergo nucleophillic aromatic substitution giving the 8-chloroanalog 116 (Scheme 44). 
 
Scheme 44. Second possible mechanism for the formation of the 8-chloroanalog (??) if 
nucleophillic attack occurred in the five-membered ring. 
The third possibility for the formation of the 8-chloroanalog 116 is metal-halogen exchange. 
When the compound 115 reacts with butyl lithium, a lithium complex can form (119), and 
followed by trapping with a chlorine electrophile gives compound 116 (Scheme 45). 
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Scheme 45. Third possible mechanism for the formation of the 8-chloroanalog (116) if n-
BuLi were present during the reaction. 
 
4.2.4 Synthesis of 9-allyl-8-bromo-6-chloro-9H-purine (120a) 
Synthesis of 9-allyl-8-bromo-6-chloro-9H-purine (120a) proved to be challenging mainly 
because of incompatibility of the allyl group in compound 98a with the reaction conditions.  
 
Scheme 46. Reagents and conditions: 1) LDA, 2) Br2C2Cl4 or NBS, THF, -78ºC, 1-2 h. 
 
When the standard lithiation-bromination procedure (0.5 mmol starting material, quenched 2 
h after addition of electrophile) was used on compound 98a, a highly complex mixture was 
obtained. Isolation of the products in pure form was not possible, however, NMR analysis and 
ESI MS of the isolated mixtures revealed the possible identities of the by-products (Scheme 
46). The inseparability of mixtures with compounds containing chloro and bromo species has 
been reported.
83
 In our case, it was not possible to identify the exact compounds formed. 
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Of particular interest in this case were the dichloro- and dibromo- compounds 121a-b and 
122a-b respectively. In order to investigate if such compounds can also form when simpler 9-
alkyl-6-chloropurines are used as substrates, the lithiation-bromination procedure was 
repeated on compound 111, (Scheme 47) the MS (ESI) of the crude product showed that only 
compound 113 was formed. 
 
Scheme 47. Reagents and conditions: 1) LDA, 2) Br2C2Cl4, THF, -78ºC, 1 h. 
In order to investigate if compound 98a can tolerate more LDA, the equivalents of LDA was 
increased from 1.4 to 5 equivalents. However, a complex mixture was obtained. We 
discovered that high equivalents of LDA together with 1,2-dibromo-1,1,2,2-tetrachloroethane 
was incompatible.  
Seeing that high equivalents of LDA together with 1,2-dibromo-1,1,2,2-tetrachloroethane is 
incompatible, compound 98a was treated with 5 equivalents of LDA followed by quenching 
with water, but complete decomposition was observed.  
To investigate the preference of deprotonation at C-8 Vs double bond migration, compound 
98a was treated with LDA (1.4 eq) and then quenched by water (Scheme 48). Compound 78 
was not formed, but quantitative recovery of 62a was possible, this concludes that LDA 
mostly deprotonates on the C-8 position and 1.4 eq of LDA is suitable for compound 62a. 
 
 
Scheme 48. Reagents and conditions: 1) LDA, 2) H2O, THF, -78ºC, 1 h. 
Ideally, further testing between 1.4 to 5 equivalents would uncover the optimal equivalents of 
LDA that should be used to carry out lithiation-bromination on compound 98a. 
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Compound 98a was stirred with Br2C2Cl4 at -78ºC for one hour gave full recovery of starting 
material. Neither halogen-exchange nor decomposition was observed.  
The reaction (Scheme 46) was upscaled to 1 mmol starting material using standard procedure 
and purified by flash chromatography. The first, last and middle fractions were separately 
evaporated, to investigate which product or by-products elutes first, but all fractions showed 
presence of all products. Total ca. 37% mixed fractions (based on the molecular weight of 
compound 120). 
The reaction (Scheme 46) then was done at 1 mmol start material but was quenched at 1 h 
instead of 2 h to investigate if a shorter reaction time will result in formation of fewer by-
products.  Just as much by-products were formed.  
The reaction (Scheme 46) was repeated with 2 mmol start material, quenched at 1 hour, 
purified via flash chromatography and finally recrystallized to obtain characterisation data for 
compound 120a from this reaction. A mixture of desired compound 120a and its migrated 
analog 120c was obtained in yields of 9 % and 0.3 %.  
Another brominating agent i.e. NBS was also employed in lieu of Br2C2Cl4, however, NBS 
did not prove to be compatible under the lithiation-halogenation conditions and a complex 
mixture was obtained. Dibromine (Br2) or cyanic bromide (BrCN) were probably better 
candidates as brominating agents under lithiation conditions than NBS. 
The first possibility for the formation of the 8-chloroanalg can be due to the 8-purinyl anion 
being trapped by the chlorine electrophile of Br2C2Cl4 (Scheme 49). 
 
Scheme 49. Chlorination can occur when the 8-purinyl anion is trapped with chloride 
electrophile. 
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The bromination of compound 98a can occur as a result of nucleophillic aromatic substitution 
SNAr (Scheme 50). A Meisenheimer-like complex (125) is formed which subsequently results 
in the formation of bromo compound 126 and a chloride leaving group. 
 
 
Scheme 50. Nucleophillic substitution occuring at the C-6 position. 
 
The exchange of chlorine in the C-6 position has been reported under a different reaction 
condition (Scheme 51). 
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Scheme 51. Reagents and conditions: CH3CN, Me3SiBr, r.t., overnight.
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The other posibilities of the interchange of halogens are SNAr occuring on the C-8 position 
(Scheme 44) and metal-halogen exhange (Scheme 45).   
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4.2.5 Synthesis of 7-allyl-8-bromo-6-chloro-7H-purine (129a) 
Compound 98b was subjected to the standard lithiation-bromination conditions.(Scheme 52) 
The 
1
H NMR of the crude product indicated less decomposition than in the case of its N9- 
isomer, compound 98a (Scheme 46). 
1
H NMR of crude product showed four H-2 signals and 
possibly double bond migrated chemical shift values. Purification by flash chromatography 
gave an inseparable mixture of products.   
                  
 
Scheme 52. Reagents and conditions: 1) LDA, 2) Br2C2Cl4, THF, -78ºC, 1 h. 
The reaction was repeated on a higher scale, and the 
1
H NMR of the crude reaction mixture 
was inconclusive due to overlapping signals, however the ratio of different components 
appeared to be 17:19:6:8. This time, there was no indication of formation of the migrated 
products (129-131b) as the -CH3, N-CH= and =CH signals were not observed. Additionally, 
MS (ESI) of the crude reaction mixture indicated presence of compounds with three distinct 
molecular weights.  
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The pathways leading to the formation of the different products are assumed to be similar to 
those described for compound 98a See section 4.2.4. 
In general, the lithiation-halogenation method proved to also be incompatible with compound 
98b.  
 
4.2.6 Synthesis of 9-allyl-6,8-dichloro-9H-purine (121) 
Since the employment of Br2C2Cl4 in the synthesis of compound 120a resulted in inseparable 
differently- halogenated by-products, C2Cl6 was employed in attempt to form compound 121a 
from compound 98a (Scheme 53). 
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Scheme 53. Reagents and conditions: 1) LDA, 2) C2Cl6, THF, -78ºC, 2-30 min. 
In the first attempt, the reaction was quenched at 30 minutes. 
1
H NMR of the crude product 
showed a full conversion but also indicated decomposition of the allyl chain. The crude 
product was purified by flash chromatography and gave a mixture of compounds 121a and 
121b in the ratio of 1: 0.03 in the yield of 15%. A low yield was obtained and we assumed 
that the rest decomposed. Compound 121b was identified as the Z-isomer according to the 
characteristic coupling constants of the Z-olefins. 
Compound 98a was stirred with C2Cl6 at -78ºC. After 1 hour, 1H NMR of the mixture 
showed no decomposition. After 2.5 hours, still no decomposition observed. The reaction 
afforded full recovery of starting material. Neither halogen-exchange nor decomposition was 
observed.  
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In the second attempt, the reaction was quenched after 2 minutes of adding the chlorine 
electrophile. The crude product was purified by flash chromatography, and an inseparable 
mixture was obtained (Scheme 53). 
1
H NMR showed that compound 121a was formed as the 
major product. A general ratio for the mixture of compounds 121a : (121b/121c)  : 
(121d/121e) were calculated from 
1
H NMR intergrals as 71:11:18. The reason for the a higher 
percentage of Z over E-isomers formed are still unknown. 
HMBC, correlations of -CH2 to C-4 and C-8 (Table 17) characterizes the structure of 
compound 121a (Scheme 53).  
Table 17. Selected correlation from long range HMBC spectrum for 9-allyl-6,8-dichloro-9H-
purine (121a).  X = coupling between carbon and hydrogen. 
 
 
 
 H-2 -CH2 =CH2 
C-4 X X  
C-6 X   
C-8  X  
-CH2   X 
    
HMBC correlations for the minor products (compounds 121b-e) could not be characterized 
due to the minute amount present in the mixture. MS (EI) showed a molecular weight of m/z 
262, an indication of the presence of a trichloro-compound. The minor products formed 
(compounds 121b-e) were interpreted by selective TOCSY NMR.  
The anion formed (132) from the deprotonation of compound 98a can be trapped by a 
chlorine electrophile (58) forming the trichloro-analog (121e). 
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Scheme 54. Mechanism for the formation of compounds 121d-e. 
In general, the lithiation-chlorination reaction on compound 98a gives a mixture of 
compounds (Scheme 53). 
 
4.2.7 Synthesis of 6,8-dichloro-9-ethyl-9H-purine (133) 
In order to investigate if the chlorinating agent (perchloroethane) can work on another 
substrate, compound 111 was treated with LDA followed by trapping with C2Cl6 (Scheme 
55). The reaction reached full conversion after 5 minutes and compound 133 was isolated in a 
yield of 74%. 
 
 
Scheme 55. Reagents and conditions: 1) LDA, 2) C2Cl6, THF, -78ºC, 5 min. 
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4.2.8 Synthesis of 7-allyl-6,8-dichloro-7H-purine (130a) 
Compound 98b was treated with LDA, trapped with C2Cl6 and quenched immediately 
(Scheme 56). 
1
H NMR of the crude product showed a 95% conversion of starting material and 
some decomposition. No E-isomer of compound 130b was observed on 
1
H NMR of crude 
product. Purification via flash chromatography gave an inseparable mixture with a ratio of 
compounds 130a : 130b as 1: 0.13 in a yield of 36%. 
 
Scheme 56. Reagents and conditions: 1) LDA, 2) C2Cl6, THF, -78ºC, quenched immediately. 
The mechanism for the migration of the double-bond is similar to that shown in Scheme 54 
(see Section 4.2.8). 
 
4.2.9 Synthesis of (Z)-8-bromo-9-(prop-1-en-1-yl)-8,9-dihydro-7H-purin-6-amine (135a) 
and (Z)-8-bromo-9-(1-bromoprop-1-en-1-yl)-9H-purin-6-amine (135b) 
Compound 104a was subjected to lithiation-bromination with a 1 hour reaction time, the 
expected compound 134 was not formed (Scheme 57). Instead compound 135a was isolated 
in 24 % yield.  
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Scheme 57. Reagents and conditions: 1) LDA, 2) Br2C2Cl4, THF, -78ºC, 1-3 h. 
1
H NMR shows coupling constants (Scheme 57) for compound 135a to be the the Z-isomer. 
Additionally, NOESY observation shows correlations for both double-bond protons, 
confirming that compound 135a is indeed the Z-isomer. Although correlations of N-CH to C-
4 and C-8 were missing in HMBC, correlations of NH2 to C-5 were present. Only C-8 did not 
show correaltions to protons. 
MS (EI) of an impure fraction from flash chromatography showed that compounds of two 
molecular weights were present, one is of the compound 135a, and the other compound 
should contain one extra bromine atom in its structure. 
1
H NMR showed that the likelyhood 
of the by-product structure being compound 135b (Scheme 57). Coupling constants between 
6-10 Hz identifies the Z-isomer. From COSY, the doublet (-CH3) correlates to a quartet 
(=CH). In HMBC, H-2 to C-4 and C-6 correlations were observed, and the correlations of –
CH3 to C1’ abd C2’. Suggesting that the bromine sits in the C1’ position of the allyl group 
(Table 18). 
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Table 18. Selected correlation from long range HMBC spectrum for (Z)-8-bromo-9-(1-
bromoprop-1-en-1-yl)-9H-purin-6-amine (132b).  X = coupling between carbon and 
hydrogen. 
 
 
 H-2 CH3 
C-4 X  
C-6 X  
C1’  X 
C2’  X 
 
 
Since the allylic proton can be deprotonated (See section 3.5.2), it can also form carbanion 
(136) and be trapped by a bromine electrophile giving the brominated species 137 (Scheme 
58). 
 
Scheme 58. Mechanism for the formation of possible by-product. 
 
The reaction (Scheme 57) was repeated extending the reaction time from 2 to 3 hours to 
investigate if the E-isomer can form as a result of longer reaction time, but it was not formed 
based on the 
1
H NMR of the crude product. The crude product was purified by flash 
chromatography, but all fractions contained a mixture of compounds.  
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The polarities of the compounds formed were very similar, which lead to the mixture of 
compounds eluted from the flash column. The low yield might be attributed to decomposition 
during reaction as the intensity of crude product on TLC was very weak.  
 
Since no allyl group signals were observed in the 
1
H NMR of the by-product, and methyl 
signals were observed, the double-bond migration must have further occurred as well for the 
by-product (Scheme 59). 
 
 
Scheme 59. Mechanism of double-bond migration. 
 
In order to investigate the deprotonation by LDA on compound 104a, water was added 
instead of a halogen electrophile (Scheme 60). The ratio of compounds 104a:139a:139b were 
42:53:5. The crude product was purified by flash chromatography which gave mixed 
fractions, giving calculated yield for compound 139a as 53%, compound 139b as 0.1% and 
compound 104a as 39%. This shows that LDA deprotonates both in the C-8 position and the 
allylic C-H. 
 
Scheme 60. Reagents and conditions: 1) LDA, 2) H2O, THF, -78ºC, 1 h. 
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5. Conclusion 
The regioselectivity of N-alkylations are in good agreement with literature. 
The methodology of lithiation-halogenation was applied to variety of purine derivatives in an 
attempt to introduce halogens i.e. bromine or chlorine in the C-8 position. Among the diverse 
purines subjected to this methodology, the 6-chloro derivatives proved to be suitable 
substrates, as evident from the good yields of compounds 112, 113 and 133.  
This methodology could also be applied to the adenine derivatives with a free NH2 group on 
the 6-position. However, the reactions in this case proved to be challenging as a result of high 
polarity and low solubility of the starting materials and products. 
Allyl purines proved to be incompatible with lithiation-halogenation sequence, highly 
complex mixtures and unwanted by-products were obtained. Double bond migration and 
halogen exchange were the major side reactions for allyl purine derivatives. 
Finally, it can be concluded that among the various substrates tested, 6-chloropurine 
derivatives are suitable substrates for C-8 functionalization via lithiation halogenation 
procedure. Albeit, the poorly soluble adenine derivatives could also be subjected for similar 
transformations, the requirement of high dilution and excess of LDA makes this procedure 
exigent.  
Three novel compounds (113, 133,135a) and 11 previously known compounds have been 
synthesized. 
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6. Experimental 
The 
1
H NMR spectra were recorded at 200 MHz with Bruker DPX 200 instrument or at 300 
MHz with a Bruker DPX 300 instrument or at 400 MHz with Bruker AVII 400 or at 600 MHz 
with Bruker AV 600 instrument. The 
13
C NMR spectra were recorded at 75, 100 or 600 MHz 
using the above mentioned instruments. Peak assignment in 
1
H NMR and 
13
C NMR was 
based on information obtained from HMQC and HMBC spectroscopy. Mass spectra were 
recorded on a VG Prospec sector instrument from Fission Instrument at 70 eV ionizing 
voltage and are presented as m/z (% rel. int.). Melting points were determined with  Büchi 
melting point B-545 apparatus and are uncorrected. Flash chromatography was done manually 
with silica gel from Merck (60, 40-63 μm). 
DMF and THF were obtained from MBRAUN Solvent Purification System (MB SPS-800). 
Ethylacetate, hexane and dichloromethane were purified by distillation. Diisopropylamine 
was distilled from NaH and were stored over molecular sieves (3 Å). n-BuLi was titrated with 
1,10-phenanthroline and methol in THF. 6-chloro-9-ethyl-9H-purine 111 was made by a 
former student in the group. All other starting materials were commercially available or 
synthesized.  
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6.1 N-Alkylation 
Synthesis of 6-Chloro-9-methyl-9H-purine (97a) and 6-Chloro-7-methyl-7H-purine (97b) 
 
Potassium carbonate (5.35 g, 38.7 mmol) was added to a stirring solution of 6-choloropurine 
29 (2.00 g, 12.9 mmol) in dry DMF (40 mL) at ambient temperature under N2-atm. 
Iodomethane (2.40 mL, 38.6 mmol) was added to the resulting mixture and stirred for 16h, 
filtered and evaporated in vacuo. The crude product was purified by flash chromatography on 
silica gel eluting with a gradient of 0-2 % MeOH in DCM. This gave 1.71g (78%) of 6-
chloro-9-methyl-9H-purine (98a) as a colourless solid and 0.402 g (19%) of 6-chloro-7-
methyl-7H-purine (98b) as a pale-yellow solid.  
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6-Chloro-9-methyl-9H-purine (98a) 
1
H NMR (CDCl3, 300 MHz): δ 3.92 (s, 3H, CH3), 8.08 (s, 1H, H-8), 8.74 (s, 1H, H-2) 
13
C NMR (CDCl3, 300 MHz): δ 30.3 (CH3), 131.5 (C-5), 145.6 (C-8), 151.0 (C-6), 152.0 (C-
2), 152.1 (C-4) 
MS (EI).  m/z (rel.%):  170/168 (33/100, M
+
), 133 (35), 106 (11), 79 (9) 
HR-MS. Found 168.0200 calculated for C6H5ClN4 168.0203 
M.p. 135.8-140.2˚C (lit. 138-142˚C).67 
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Spectrum 1. 
1
H NMR of 6-Chloro-9-methyl-9H-purine (97a). 
 
Spectrum 2. 
13
C NMR of 6-Chloro-9-methyl-9H-purine (97a). 
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Spectrum 3. HMQC of 6-Chloro-9-methyl-9H-purine (97a). 
 
Spectrum 4. HMBC of 6-Chloro-9-methyl-9H-purine (97a). 
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6-Chloro-7-methyl-7H-purine (97b) 
1
H NMR (CDCl3, 300 MHz): δ 4.14 (s, 3H, CH3), 8.17 (s, 1H, H-8), 8.83 (s, 1H, H-2) 
13
C NMR (CDCl3, 300 MHz): δ 34.4 (CH3), 123.0 (C-5), 143.4 (C-6), 149.4 (C-8), 152.5 (C-
2), 161.7 (C-4) 
MS (EI). m/z (rel.%): 170/168 (37/97, M
+
), 134/133 (10/100),100 (16) 
HRMS Found 168.0198 calculated for C6H5ClN4 168.5837 
M.p. 177-178˚C   
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Spectrum 5. 
1
H NMR of 6-Chloro-7-methyl-7H-purine (97b). 
 
Spectrum 6. 
13
C NMR of 6-Chloro-7-methyl-7H-purine (97b). 
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Spectrum 7.  HMQC of 6-Chloro-7-methyl-7H-purine (97b). 
 
 
Spectrum 8.  HMBC of 6-Chloro-7-methyl-7H-purine (97b). 
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Purification of 6-chloro-9-ethyl-9H-purine (111) 
 
Discolored product from several years ago was purified by flash chromatography with EtOAc. 
Colourless crystals were collected. 
   
6-chloro-9-ethyl-9H-purine (111) 
1H NMR (CDCl3, 200 MHz):  δ 1.55 (t, J = 7.2 Hz, 3H, CH3), 4.35 (q, J = 7.2 Hz, 2H, 
CH2), 8.12 (s, 1H, H-8), 8.74 (s, 1H, H-2) 
MS (EI). m/z (rel.%): 184/182 (M
+
 19/59), 167 (8), 156/154(35/100) 
HRMS Found 182.0356 calculated for 182.0359 
M.p. 82.1-82.3˚C  
 
Spectrum 9. 
1
H NMR of 6-chloro-9-ethyl-9H-purine (111). 
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Synthesis of 9-Allyl-6-chloro-9H-purine (98a)  and 7-allyl-6-chloro-7H-purine (98b) 
 
Potassium carbonate (4.15 g, 30.0 mmol) was added to a stirred solution of 6-chloropurine 29 
(1.58 g, 10.2 mmol) in dry DMF (40 mL) at ambient temperature under N2. After 20 min, 
allylbromide (1.70 mL, 19.7 mmol) was added and the resulting mixture was stirred for 20 h, 
filtered and evaporated in vacuo. The crude product was purified by flash chromatography on 
silica gel eluting with first 0.5 % MeOH in DCM followed by 1 % MeOH in DCM. This gave 
1.18 g (59%) of 9-Allyl-6-chloropurine (98a) as a colourless solid and 407 mg (20%) 7-allyl-
6-chloropurine (98b) as a yellow solid. 
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9-Allyl-6-chloro-9H-purine (98a) 
1
H NMR (CDCl3, 300 MHz): δ 4.88-4.91 (m, 2H, -CH2), 5.22-5.37 (m, 2H, =CH2), 5.97-6.10 
(m, 1H, =CH), 8.11 (s, 1H, H-8), 8.74 (s, 1H, H-2) 
13
C NMR (CDCl3, 75 MHz): δ 46.3 (-CH2), 120.0 (=CH2), 130.9 (=CH), 131.6 (C-5), 144.9 
(C-8), 151.1 (C-4), 151.7 (C-6), 152.1 (C-2) 
MS (EI).  m/z (rel. %): 195/193 (M
+
, 39/100), 167 (26), 154 (12) 
HR-MS. Found 194.0355 calculated for C8H7ClN4 194.0359 
M.p.  79.6-80.1˚C 
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Spectrum 10. 
1
H NMR of 9-Allyl-6-chloro-9H-purine (98a).  
 
 
Spectrum 11. 
13
C NMR of 9-Allyl-6-chloro-9H-purine (98a). 
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Spectrum 12. HMQC of 9-Allyl-6-chloro-9H-purine (98a). 
 
Spectrum 13. HMBC of 9-Allyl-6-chloro-9H-purine (98a). 
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7-Allyl-6-chloro-7H-purine(98b) 
1
H NMR (CDCl3, 300 MHz): δ 5.08-5.14 (m, 3H, -CH2 + =CH2a), 5.34-5.38 (dm, J=10.3 Hz, 
1H, =CH2b), 6.01-6.14 (m, 1H, =CH), 8.22 (s, 1H, H-8), 8.87 (s, 1H, H-2) 
13
C NMR (CDCl3, 75 MHz): δ 49.2 (-CH2), 119.5 (=CH2), 122.4 (C-5), 131.7 (=CH), 143.0 
(C-6), 148.8 (C-8), 152.5 (C-2), 161.9 (C-4)  
MS (EI). m/z (rel. %):  196/194 (M
+
, 39/100), 167 (13), 159 (10) 
HR-MS Found 194.357 calculated for 194.0359 
M.p. 92.8-93.0˚C 
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Spectrum 14. 
1
H NMR of 7-Allyl-6-chloro-7H-purine (98b).   
 
 
Spectrum 15. 
13
C NMR of 7-Allyl-6-chloro-7H-purine (98b). 
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Spectrum 16. HMQC of 7-Allyl-6-chloro-7H-purine (98b). 
 
Spectrum 17. HMBC of 7-Allyl-6-chloro-7H-purine (98b). 
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Synthesis of 9-methyl-9H-purin-6-amine (99a) 
 
Water was removed from TBAF•3H2O (11.7 g, 37.2 mmol) by dissolving in toluene (100 mL) 
and evaporated in vacuo five times. The TBAF was then dried under high vacuum overnight. 
Adenine 9 (2.50 g, 18.5 mmol) was added to the solution of dried TBAF in THF (100 mL) at 
ambient temperature under N2. Iodomethane (4.60 mL, 74.0 mmol) was added and the 
resulting mixture was stirred under N2 for 1.5h. The mixture was evaporated in vacuo, 
dissolved in methanol (50 mL) and vacuum filtered. This gave 2.01 g (75%) of 9-methyl-9H-
purin-6-amine (99a) as a colourless solid. 
 
85 
 
9-methyl-9H-purin-6-amine (99a)  
1H NMR (DMSO-d6, 300 MHz): δ 3.70(s, 3H, CH3), 7.14 (s, 2H, NH2), 8.07 (s, 1H, H-8), 
8.13 (s,1H, H-2) 
13C NMR (DMSO-d6, 75 MHz): δ 29.3 (CH3), 118.6 (C-5), 141.3 (C-8), 149.8 (C-4), 152.4 
(C-2), 155.9 (C-6) 
MS (EI). m/z (rel.%): 149 (M
+
 100), 122 ( 19), 42 (10) 
HR-MS. Found 149.0704 calculated for C6H7N5 149.0701 
M.p. 286-289˚C 
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Spectrum 18. 
1
H NMR of 9-methyl-9H-purin-6-amine (99a).   
 
Spectrum 19. 
13
C NMR of 9-methyl-9H-purin-6-amine (99a). 
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Spectrum 20. HMQC of 9-methyl-9H-purin-6-amine (99a). 
 
Spectrum 21. HMBC of 9-methyl-9H-purin-6-amine (99a). 
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Synthesis of 9-Ethyl-9H-purin-6-amine (101a) and N,9-diethyl-9H-purin-6-amine (101c) 
 
Method A  
To a mixture of adenine 9 (1.35 g, 10.0 mmol) and cesium carbonate (3.91 g, 12.0 mmol) in 
DMF (15 mL) was added iodoethane (0.96 mL, 11.9 mmol) at r.t. The reaction mixture was 
stirred at 50˚C for 16h and quenched with water (25 mL), evaporated in vacuo and purified by 
flash chromatography (2-10% MeOH in DCM). This gave 1.40 g (86%) of 9-ethyl-9H-purin-
6-amine (101a) as a colourless solid and 45 mg (2%) of N,9-diethyl-9H-purin-6-amine (101c ) 
as an off-white solid. 
Method B 
To a mixture of adenine 9 (1.25 g, 9.28 mmol) and cesium carbonate (3.70 g, 11.1 mmol) in 
DMF (15 mL) was added iodoethane (0.91 mL, 11.1 mmol) at r.t. The reaction mixture was 
stirred at r.t. for 16h and quenched with water (25 mL), evaporated in vacuo and purified by 
flash chromatography (2-10% MeOH in DCM).   This gave 1.25 g (83%) of 9-ethyl-9H-
purin-6-amine (101a) as a colourless solid. 
Method C 
TBAF•3H2O (3.16 g, 10.0 mmol) was dried with toluene (25 mL) via evaporation in vacuoe 
five times and stored under high vacuum overnight. To the dried TBAF, adenine 9 (673 mg, 
5.00 mmol) and dry THF (25 mL) was added and stirred at r.t. under N2-atm. Iodoethane 
(1.75 mL, 23.7 mmol) was added to the stirring mixture. The reaction was stirred for 5h and 
evaporated in vacuo. The crude product was then purified via flash chromatography eluting 
with acetone. The collected colourless crystals were repurified via flash chromatography 
eluting with DCM followed by acetone: DCM (1:1), followed by ethanol. This gave 681 mg 
(84%) of 9-ethyl-9H-purin-6-amine (101a) as a colourless solid. 
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9-Ethyl-9H-purin-6-amine (101a) 
1
H NMR (DMSO-d6, 300 MHz): δ 1.38 (t, J=7.2 Hz, 3H, CH3), 4.15 (q, J=7.2 Hz, 2H, CH2), 
7.19 ( s, 2H, NH2), 8.14 ( s, 2H, H-2 + H-8) 
13C NMR (DMSO-d6, 75 MHz): δ 15.2 (CH3), 38.0 (CH2), 118.8 (C-5), 140.4 (C-2), 149.3 
(C-4), 152.3 (C-8), 155.9 (C-6)  
MS (EI). m/z (rel.%): 163(M
+ 
100), 135( 95), 108( 58) 
HRMS Found 163.0859 calculated for C7H9N5 163.0860 
M.p. 196.1-196.3 ˚C 
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Spectrum 22. 
1
H NMR of 9-Ethyl-9H-purin-6-amine (101a). 
 
 
Spectrum 23. 13C NMR of 9-Ethyl-9H-purin-6-amine (101a). 
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Spectrum 24. HMQC of 9-Ethyl-9H-purin-6-amine (101a). 
 
 
Spectrum 25. HMBC of 9-Ethyl-9H-purin-6-amine (101a). 
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N,9-diethyl-9H-purin-6-amine (101c) 
1
H NMR (DMSO-d6, 300MHz): δ 1.16 (t, J=7.2 Hz, 3H, CH3), 1.38 (t, J=7.2 Hz, 3H, ´CH3), 
3.51 (bs, 2H, CH2), 4.15 (q, J=7.2 Hz, 2H, ´CH2), 8.06 (s, 1H, H-8), 8.22 (s, 1H, H-2) 
13
C NMR (DMSO-d6, 75MHz): δ 14.9 (CH3), 15.3 (´CH3), 34.5 (CH2), 38.0 (´CH2), 119.1 
(C-4), 140.0 (C-8), 148.5 (C-5), 152.3 (C-2), 154.4 (C-6) 
MS (EI). m/z (rel. %):192 (M
+
 100), 176 (99), 163(31),148 (59) 
HR-MS. Found 191.1169 calculated for C9H13N5 191.1171 
M.p. 108.6-109.2 ºC 
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Spectrum 26. 
1
H NMR of N,9-diethyl-9H-purin-6-amine(101c). 
 
Spectrum 27. 
13
C NMR of N,9-diethyl-9H-purin-6-amine(101c). 
 
94 
 
 
Spectrum 28. HMQC of N,9-diethyl-9H-purin-6-amine(101c). 
 
 
 
Spectrum 29. HMBC of N,9-diethyl-9H-purin-6-amine(101c). 
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Spectrum 30. COSY of N,9-diethyl-9H-purin-6-amine(101c). 
 
Spectrum 31. NOESY of N,9-diethyl-9H-purin-6-amine(101c). 
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Synthesis of 9-allyl-9H-purin-6-amine (104a) and 3-allyl-3H-purin-6-amine (104c) 
 
To a stirred suspension of adenine 9 (270 mg, 2.00mmol) in dry DMF (8 mL) was added in 
small portions NaH (60% in oil) (80 mg, 2.00 mmol) at r.t. After 2 h of stirring, allylbromide 
(0.27 mL, 3.14 mmol) was added dropwise, and the mixture was stirred for 2 h at r.t. The 
reaction mixture was evaporated in vacuo and purified by flash chromatography (eluent 
gradient of 5-10% MeOH in DCM followed by EtOH). This gave 144 mg (41%) of 9-allyl-
9H-purin-6-amine (104a) as a colourless solid and 45 mg (13%) of 3-allyl-3H-purin-6-amine 
(104c) as an off-white solid. 
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9-allyl-9H-purin-6-amine (104a) 
1
H NMR (CDCl3, 300 MHz): δ 4.79-4.81 (m, 2H, -CH2), 5.16-5.32 (m, 2H, =CH2), 5.72 (bs, 
2H, NH2), 5.96-6.09 (m, 1H, =CH), 7.79 (s, 1H, H-8), 8.36 (s, 1H, H-2) 
13
C NMR (CDCl3, 75 MHz): δ 45.8 (-CH2), 119.0 (=CH2), 119.6 (C-5), 131.8 (=CH), 140.4 
(C-8), 150.1 (C-4), 153.1 (C-2), 155.4 (C-6) 
MS (EI). m/z (rel. %): 176 (10), 175(84, M
+
), 174 (100), 148 (20), 135 (11) 
HR-MS. Found 175.0852 calculated for C8H9N5 175.0858 
M.p. 153.8-154.2 ˚C 
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Spectrum 32. 
1
H NMR of 9-allyl-9H-purin-6-amine (104a). 
 
Spectrum 33. 
13
C NMR of 9-allyl-9H-purin-6-amine (104a). 
99 
 
 
 
Spectrum 34. HMQC of 9-allyl-9H-purin-6-amine (104a). 
 
Spectrum 35. HMBC of 9-allyl-9H-purin-6-amine (104a). 
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3-allyl-3H-purin-6-amine (104c) 
A measurement in CDCl3 is in good agreement with literature. Due to good solubility of the 
compound in DMSO-d6, the values are reported in DMSO-d6. 
1
H NMR (DMSO-d6, 300 MHz): δ 4.93 (m, 2H, -CH2), 4.94-5.25 (m, 2H, =CH2), 6.05-6.18 
(m, 1H, =CH), 7.79 (s, 1H, H-8), 7.96 (bs, 2H, -NH2), 8.34 (s, 1H, H-2) 
13
C NMR (DMSO-d6, 75 MHz): 50.9 (-CH2), 118.7 (=CH2), 119.9 (C-5), 132.5 (=CH), 143.4 
(C-2), 149.5 (C-4), 152.1 (C-8), 154.8 (C-6)  
MS (EI). m/z (rel. %):  176 (8), 175 (M
+ 
64), 174 (100),  148 (16), 147 (21), 135 (11) 
HR-MS. Found 175.0855 calculated for C6H9N5 175.0858 
M.p. 194.5-194.9 ˚C 
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Spectrum 36. 
1
H NMR of 3-allyl-3H-purin-6-amine (104c). 
 
Spectrum 37. 
13
C NMR of 3-allyl-3H-purin-6-amine (104c). 
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Spectrum 38. HMQC of 3-allyl-3H-purin-6-amine (104c). 
 
Spectrum 39. HMBC of 3-allyl-3H-purin-6-amine (104c). 
4.2 Lithiation/Bromination 
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6.2 Lithiation-Bromination  
Synthesis of 8-bromo-6-chloro-9-methyl-9H-purine (112) 
 
A solution of diisopropylamine (0.11 mL, 0.75 mmol) in dry THF (2 mL) was cooled to -78ºC 
under N2-atm. 0.39 M n-BuLi in hexane (1.78 mL, 0.70mmol) was added dropwise and the 
mixture was stirred at -78ºC under N2-atm for 1 h.  6-chloro-9-methyl-9H-purine 97a (84 mg, 
0.50 mmol) was dissolved in dry THF (2 mL) and added dropwise to the reaction mixture and 
stirred at -78ºC under N2-atm for 1 h. Br2C2Cl4 (326 mg, 1.00mmol) was dissolved in dry 
THF (1 mL) and added to the reaction mixture and stirred at -78ºC under N2-atm for 1 h. Sat. 
aq. NH4Cl (15 mL) was added and the mixture was left to warm up to r.t.,  and extracted with 
EtOAc ( 3 x 25 mL). The combined organic extracts were washed with brine (20 mL), dried 
(MgSO4) and evaporated in vacuo. The crude product was purified by flash chromatography 
eluting with DCM followed by 0.5% MeOH in DCM. This gave 99 mg (80%) of 8-bromo-6-
chloro-9-methyl-9H-purine (112) as an off-white solid. 
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8-bromo-6-chloro-9-methyl-9H-purine (112) 
1
H NMR (CDCl3, 300 MHz): δ 3.86 (s, 3H, CH3), 8.69(s, 1H, H-2) 
13
C NMR (CDCl3, 75 MHz): δ 31.1 (CH3), 131.8 (C-5), 134.8 (C-8), 149.4 (C-6), 152.0 (C-
2), 153.0 (C-4) 
MS (EI). m/z (rel. %):  250/248/246 (24/100/77 M
+
), 211( 22), 167( 25), 105( 15) 
HR-MS. Found 245.9313 calculated for C6H4BrClN4 245.9308 
M.p. 180.3-182.0˚C (lit. 187 ˚C).85 
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Spectrum 40. 
1
H NMR of 8-bromo-6-chloro-9-methyl-9H-purine (112). 
 
 
Spectrum 41. 
13
C NMR of 8-bromo-6-chloro-9-methyl-9H-purine (112). 
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Spectrum 42.  HMQC of 8-bromo-6-chloro-9-methyl-9H-purine (112). 
 
 
Spectrum 43. HMBC of 8-bromo-6-chloro-9-methyl-9H-purine (112). 
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Synthesis of 8-bromo-6-chloro-9-ethyl-9H-purine (113) 
 
A solution of diisopropylamine (0.11 mL, 0.75 mmol) in dry THF (2 mL) was cooled to -78ºC 
under N2-atm. 1.48 M n-BuLi in hexane (0.47 mL, 0.70mmol) was added dropwise and the 
mixture was stirred at -78ºC under N2-atm for 1 h.  6-chloro-9-ethyl-9H-purine 111 (91 mg, 
0.50 mmol) was dissolved in dry THF (2 mL), added dropwise to the reaction mixture and 
stirred at -78ºC under N2-atm for 1 h. Br2C2Cl4 (326 mg, 1.00mmol) was dissolved in dry 
THF (1 mL) and added to the reaction mixture and stirred at -78ºC under N2-atm for 1 h. Sat. 
aq. NH4Cl (15 mL) was added and the mixture was left to warm up to r.t.,  and extracted with 
EtOAc ( 3 x 25 mL). The combined organic extracts were washed with brine (20 mL), dried 
(MgSO4) and evaporated in vacuo. The crude product was purified by flash chromatography 
eluting with 4% MeOH in DCM gave brown solid. The brown solid was recrystallized with 
ice-cold hexane. This gave 113 mg (86%) of 8-bromo-6-chloro-9-ethyl-9H-purine (113) as a 
brown solid. 
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8-bromo-6-chloro-9-ethyl-9H-purine (113) 
1
H NMR (CDCl3, 300 MHz): δ 1.46 (t, J = 7.2 Hz, 3H, CH3), 4.35(q, J = 7.2 Hz, 2H, CH2), 
8.68 (s, 1H, H-2) 
13
C NMR (CDCl3, 75 MHz): δ 14.6 (CH3), 40.3 (CH2), 131.9 (C-5), 133.89 (C-8), 149.4 (C-
6), 151.9 (C-2), 152.5 (C-4) 
MS (EI). m/z (rel.%): 264/262/260 (M
+
, 11/46/36), 236/234/232 (25/100/79), 199/197 
(10/10), 183/181 (4/14) 
HR-MS. Found 259.9460 calculated for C7H6BrClN4 259.9464 
M.p. 169.1-169.4˚C  
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Spectrum 44. 
1
H NMR of 8-bromo-6-chloro-9-ethyl-9H-purine (113). 
 
 
Spectrum 45. 
13
C NMR of 8-bromo-6-chloro-9-ethyl-9H-purine (113). 
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Spectrum 46. HMQC of 8-bromo-6-chloro-9-ethyl-9H-purine (113). 
 
Spectrum 47. HMBC of 8-bromo-6-chloro-9-ethyl-9H-purine (113). 
111 
 
8-bromo-9-methyl-9H-purin-6-amine (114) 
 
A solution of diisopropylamine (0.38 mL, 2.70 mmol) in dry THF (2 mL) was cooled to -78ºC 
under N2-atm. 1.23 M n-BuLi in hexane (2.05 mL, 2.52 mmol) was added dropwise and the 
mixture was stirred at -78ºC under N2-atm for 1 h.  A stirring suspension of 9-methyl-9H-
purin-6-amine (99a) (75 mg, 0.50 mmol) in dry THF (60 mL) was cooled to -78ºC under N2-
atm.  The LDA solution was added dropwise to the suspension and stirred at -78ºC under N2-
atm for 1 h. Br2C2Cl4 (326 mg, 1.00mmol) was dissolved in dry THF (1 mL) and added to the 
reaction mixture and stirred at -78ºC under N2-atm for 2 h. Sat. aq. NH4Cl (2 mL) was added 
and the mixture was left to warm up to r.t. The mixture was extracted with EtOAc (7 x 25 mL 
plus 14 x 10 mL). The combined organic extracts were washed with brine (20 mL), dried 
(MgSO4) and evaporated in vacuo. The crude product was purified by flash chromatography 
eluting with a gradient of 3-14% MeOH in DCM. This gave 80 mg (70%) of 8-bromo-9-
methyl-9H-purin-6-amine (114) as an off-white solid. 
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8-bromo-9-methyl-9H-purin-6-amine (114) 
1
H NMR (DMSO-d6, 300 MHz): δ 3.64 (s, 3H, CH3), 7.36 (s, 2H, NH2), 8.12 (s, 1H, H-2) 
13
C NMR (DMSO-d6, 75 MHz): δ 30.1 (CH3), 119.0 (C-5), 127.1 (C-8), 150.9 (C-4), 152.8 
(C-2), 154.7 (C-6) 
MS (EI). m/z (rel. %): 229/227 (M
+
 100/96), 202/200 (19/19), 121 (13) 
HR-MS. Found 226.9810 calculated for C6H6BrN5 226.9807 
M.p. 302.4-303.0 ˚C 
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Spectrum 48. 
1
H NMR of 8-bromo-9-methyl-9H-purin-6-amine (114). 
 
 
 
Spectrum 49. 
13
 C NMR of 8-bromo-9-methyl-9H-purin-6-amine (114). 
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Spectrum 50. HMQC of 8-bromo-9-methyl-9H-purin-6-amine (114). 
 
Spectrum 51. HMBC of 8-bromo-9-methyl-9H-purin-6-amine (114). 
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Synthesis of 8-bromo-9-ethyl-9H-purin-6-amine (115) and 8-chloro-9-ethyl-9H-purin-6-
amine (116) 
 
 
A solution of diisopropylamine (0.38 mL, 2.70 mmol) in dry THF (4 mL) was cooled to -78ºC 
under N2-atm. 0.55 M n-BuLi in hexane (4.5 mL, 2.48 mmol) was added dropwise and the 
mixture was stirred at -78ºC under N2-atm for 1 h. A stirring suspension of 9-ethyl-9H-purin-
6-amine 101a (82 mg, 0.50 mmol) in dry THF (15 mL) was cooled to -78ºC under N2-atm. 
The LDA solution was added dropwise to the suspension and stirred at -78ºC under N2-atm 
for 1 h. Br2C2Cl4 (327 mg, 1.00mmol) was dissolved in dry THF (1 mL) and added to the 
reaction mixture and stirred at -78ºC under N2-atm for 3 h. Sat. aq. NH4Cl (15 mL) was added 
and the mixture was left to warm up to r.t. The mixture was extracted with EtOAc (5 x 25 
mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO4) and 
evaporated in vacuo. The crude product was purified by flash chromatography eluting with a 
gradient of 5-11% MeOH in DCM. This gave a 86 mg mixture 8-bromo-9-methyl-9H-purin-
6-amine (115) and 8-bromo-9-methyl-9H-purin-6-amine (116) as an off-white solid.  
The ratio compounds 115 : 116 was 7 : 1, calculated from 
1
H NMR. 
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8-bromo-9-ethyl-9H-purin-6-amine (115) and 8-chloro-9-ethyl-9H-purin-6-amine (116) 
 
1
H NMR (CDCl3, 300 MHz): δ 1.30 (t, J = 7.2 Hz, 3H, CH3), 4.14 (q, J = 7.2 Hz, 2H, CH2), 
7.36 (s, 2H, NH2), 8.12 (s, 1H, H-2 of compound 115), 8.15 (s, 1H, H-2 of compound 116) 
13
C NMR (CDCl3, 75 MHz): δ 14.6 (CH3), 38.9 (CH2), 119.1 (C-5), 125.9 (C-8), 150.4 (C-
4), 152.8 (C-2), 154.7 (C-6) 
MS (ESI). 244/242 (M+H), 200/198 (M+H)  
HR-MS. Found 240.9967 calculated for C7H8BrN5 240.9963 
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Spectrum 52. 
1
H NMR of 8-bromo-9-ethyl-9H-purin-6-amine (115) and 8-chloro-9-ethyl-
9H-purin-6-amine (116). 
 
 
Spectrum 53. 
1
H NMR of 8-bromo-9-ethyl-9H-purin-6-amine (115) and 8-chloro-9-ethyl-
9H-purin-6-amine (116). 
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Spectrum 54. HMQC of of 8-bromo-9-ethyl-9H-purin-6-amine (115) and 8-chloro-9-ethyl-
9H-purin-6-amine (116).  
 
Spectrum 55. HMBC of of 8-bromo-9-ethyl-9H-purin-6-amine (115) and 8-chloro-9-ethyl-
9H-purin-6-amine (116). 
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Synthesis of 9-allyl-8-bromo-6-chloro-9H-purine (120a) and (Z)-8-bromo-6-chloro-9-
(prop-1-en-1-yl)-9H-purine (120c) 
  
A solution of diisopropylamine (0.42 mL, 3.00 mmol) in dry THF (8 mL) was cooled to -78ºC 
under N2-atm. 1.33 M n-BuLi in hexane (2.10 mL, 2.80 mmol) was added dropwise over 10 
min and the mixture was stirred at -78ºC under N2-atm for 1 h. 9-Allyl-6-chloro-9H-purine 
98a (390 mg, 2.00 mmol) was dissolved in dry THF (8 mL) and added dropwise over 10 min 
to the reaction mixture and stirred at -78ºC under N2-atm for 1 h. Br2C2Cl4 (1.30 g, 
4.00mmol) in dry THF (4 mL) was added dropwise over 10 min and the resulting  mixture 
was stirred at -78ºC under N2-atm for 1 h. Sat. aq. NH4Cl (60 mL) was added and the mixture 
was left to warm up to r.t., and extracted with EtOAc (3 x 100 mL). The combined organic 
extracts were washed with brine (80 mL), dried (MgSO4) and evaporated in vacuo. The crude 
product was purified by flash chromatography eluting with 0.5-10% MeOH in DCM gave a 
yellow solid. The yellow solid was recrystallized with ice-cold hexane. This gave 52 mg 
mixture of 9-allyl-8-bromo-6-chloro-9H-purine (120a) and (Z)-8-bromo-6-chloro-9-(prop-1-
en-1-yl)-9H-purine (120c) as an off-white solid.  
The ratio of compounds 120a : 120c were 30 : 1, calculated from 
1
H NMR. 
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9-allyl-8-bromo-6-chloro-9H-purine (120a) 
1
H NMR (CDCl3, 300 MHz): δ 1.60-1.63 (dd, J = 1.5 Hz and J = 6.9 Hz, 3H, -CH3 of 
compound 120c), 4.90 (d, J = 5.4 Hz, 2H, -CH2), 5.10-5.30 (m, 2H, =CH), 6.20-6.30 (m, 1H, 
=CH-CH3 of compound 120c), 6.47-6.50 (d, 1H, N-CH of compound 120c) 8.69 (s, 1H, H-2) 
13
C NMR (CDCl3, 75 MHz): δ 46.8 (-CH2), 119.5 (=CH2), 129.9 (=CH2), 129.9 (=CH), 131.8 
(C-5), 134.2 (C-8), 149.5 (C-6), 152.1 (C-2), 152.7 (C-4) 
MS (ESI) 277/275/273 (M+H) 
The carbon shift values for compound 120c was not determined due to very low signal 
intensity. 
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Spectrum 56. 
1
H NMR of 9-allyl-8-bromo-6-chloro-9H-purine (120a) and (Z)-8-bromo-6-
chloro-9-(prop-1-en-1-yl)-9H-purine (120c). 
 
 
 
Spectrum 57. 
13
C NMR of 9-allyl-8-bromo-6-chloro-9H-purine (120a) and (Z)-8-bromo-6-
chloro-9-(prop-1-en-1-yl)-9H-purine (120c). 
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Spectrum 58. HMQC of 9-allyl-8-bromo-6-chloro-9H-purine (120a) and (Z)-8-bromo-6-
chloro-9-(prop-1-en-1-yl)-9H-purine (120c). 
 
 
 
Spectrum 59. HMBC of f 9-allyl-8-bromo-6-chloro-9H-purine (120a) and (Z)-8-bromo-6-
chloro-9-(prop-1-en-1-yl)-9H-purine (120c). 
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7-allyl-8-bromo-6-chloro-7H-purine (129a) 
 
Diisopropylamine (0.42 mL, 3.00 mmol) in THF (8 mL) was cooled to -78 ºC under N2-atm. 
1.33 M n-BuLi in hexane (2.10 mL, 2.80 mmol) was added dropwise over 10 min and the 
mixture was stirred at -78 ºC under N2-atm for 1 h. 7-allyl-6-chloro-7H-purine 98b (390 mg, 
2.00 mmol) in THF  (8 mL) was added dropwise over 10 min to the mixture and stirred at -78 
ºC under N2-atm for 1 h. Br2C2Cl4 (1.30g, 4.00 mmol) in THF (4 mL) was added dropwise 
over 10 min. The resulting mixture was stirred for 1 h. Sat. aq. NH4Cl (60 mL) was added and 
the mixture was left to warm up to r.t., and extracted with EtOAc (3 x 100 mL). The 
combined organic extracts were washed with brine (80 mL), dried (MgSO4) and evaporated in 
vacuo. The crude product was purified by flash chromatography eluting with 0-2 % MeOH in 
DCM gave a yellow solid. The yellow solid was recrystallized with ice-cold hexane. This 
gave 36 mg of a mixture of compounds as colourless needles.  
No yields were reported for the mixture. 
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Spectrum 60. 
1
H NMR for the mixture of compounds 129a-c, 130a-b, 131a-b. 
 
 
Spectrum 61. 
13
C NMR for the mixture of compounds 129a-c, 130a-b, 131a-b. 
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Spectrum 62. HMQC for the mixture of compounds 129a-c, 130a-b, 131a-b. 
 
 
Spectrum 63. HMBC for the mixture of compounds 129a-c, 130a-b, 131a-b. 
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Spectrum 64. COSY for the mixture of compounds 129a-c, 130a-b, 131a-b. 
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Synthesis of (Z)-8-bromo-9-(prop-1-en-1-yl)-9H-purin-6-amine (132a) and (Z)-8-bromo-
9-(1-bromoprop-1-en-1-yl)-9H-purin-6-amine (132b) 
 
 
Diisopropylamine (0.38 mL, 2.70 mmol) in THF (2 mL) was cooled to -78ºC under N2-atm. 
1.23 M n-BuLi in hexane (2.05 mL, 2.52 mmol) was added dropwise over 10 min, and the 
mixture was stirred for 1 h at -78ºC under N2-atm. 9-Allyladenine 104a (88 mg, 0.50 mmol) 
was dissolved in THF (15 mL) and added dropwise to the mixture over 10 min and stirred for 
1 h at -78ºC under N2-atm. Br2C2Cl4 in THF (1 mL) was added dropwise to the mixture over 
10 min and stirred for 2 h at -78ºC under N2-atm.  Sat. aq. NH4Cl (15 mL) was added and the 
mixture was left to warm up to r.t. and extracted with EtOAc (9 x 25 mL). The combined 
organic extractes were washed with brine (20 mL), dried (MgSO4) and evaporated in vacuo. 
The crude product was purified via flash chromatography eluting with 0-2% MeOH in DCM 
gave 30 mg (24%) of (Z)-8-bromo-9-(prop-1-en-1-yl)-9H-purin-6-amine as a brown solid and 
(Z)-8-bromo-9-(1-bromoprop-1-en-1-yl)-9H-purin-6-amine (132b) in a mixture. 
The presence of compound 132b was observed by NMR in the impure fraction, but ratio was 
undetermined due to signal overlap. (See appendix Spectra 74-77) 
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(Z)-8-bromo-9-(prop-1-en-1-yl)-9H-purin-6-amine (132a)  
1
H NMR (CDCl3, 400 MHz): δ 1.61-1.63 (dd, J = 1.2 Hz and J = 7.2 Hz, 3H, CH3), 5.98 (bs, 
2H, NH2), 6.14-6.21 (dq, 1H, =CH-CH3), 6.43-6.45 (dd, J = 1.2 Hz and J = 7.6 Hz) 1H, N-
CH), 8.32 (s, 1H, H-2) 
13
C NMR (CDCl3, 100 MHz): δ 13.3 (CH3), 119.9 (C-5), 120.1 (=CH-CH3), 127.4 (C-8), 
132.0 (N-CH), 151.6 (C-4 or C-6), 153.4 (C-2), 154.3 (C-4 or C-6) 
MS (EI).  m/z (rel.%): 255/253 (M
+
 23/23), 175 (10), 174 (100), 157 (10) 
HR-MS Found 252.9971 calculated for C8H8BrN5 252.9963 
M.p. 91.4-91.9 ºC 
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Spectrum 65. 
1
H NMR of (Z)-8-bromo-9-(prop-1-en-1-yl)-9H-purin-6-amine (132a). 
 
Spectrum 66. 
13
C NMR of (Z)-8-bromo-9-(prop-1-en-1-yl)-9H-purin-6-amine (132a). 
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Spectrum 67. HSQC of (Z)-8-bromo-9-(prop-1-en-1-yl)-9H-purin-6-amine (132a). 
 
Spectrum 68. HMBC of (Z)-8-bromo-9-(prop-1-en-1-yl)-9H-purin-6-amine (132a). 
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Spectrum 69. NOESY of (Z)-8-bromo-9-(prop-1-en-1-yl)-9H-purin-6-amine (132a). 
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6.3 Lithiation-Chlorination  
Synthesis of 6,8-dichloro-9-ethyl-9H-purine (133) 
 
A solution of diisopropylamine (0.11 mL, 0.75 mmol) in dry THF (2 mL) was cooled to -78ºC 
under N2-atm. 1.33 M n-BuLi in hexane (0.53 mL, 0.70 mmol) was added dropwise over 10 
min and the mixture was stirred at -78ºC under N2-atm for 1 h. 6-Chloro-9-ethyl-9H-purine 
111 (91 mg, 0.50 mmol) in dry THF (2 mL) was added dropwise over 10 min to the reaction 
mixture and stirred at -78ºC under N2-atm for 1 h. C2Cl6 (237 mg, 1.00 mmol) was dissolved 
in dry THF (1 mL) and added dropwise over 10 min to the reaction mixture and stirred at -
78ºC under N2-atm for 5 minutes. Sat. aq. NH4Cl (15 mL) was added and the mixture was left 
to warm up to r.t., and extracted with EtOAc (2 x 25 mL). The combined organic extracts 
were washed with brine (20 mL), dried (MgSO4) and evaporated in vacuo. The crude product 
was purified by flash chromatography eluting with 0-3% MeOH in DCM gave yellow solid. 
The yellow solid was recrystallized with ice-cold hexane. This gave 81 mg (74%) of 6,8-
dichloro-9-ethyl-9H-purine (133) as a yellow solid. 
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6,8-dichloro-9-ethyl-9H-purine (133) 
1
H NMR (CDCl3, 300 MHz): δ 1.47 (t, J = 7.2 Hz, 3H, CH3), 4.35 (q, J = 7.2 Hz, 2H, CH2), 
8.71 (s, 1H, H-2) 
13
C NMR (CDCl3, 300 MHz): δ 14.5 (CH3), 39.4 (CH2), 130.7 (C-5), 144.2 (C-8), 149.5 (C-
6), 152.0 (C-2), 152.2 (C-4) 
MS (EI). m/z (rel.%): 220/218/216 (5/30/46 M
+
), 192/190/188 (10/65/100), 155/153(7/21) 
HR-MS Found 215.9963 calculated for C7H6Cl2N4 215.9970 
M.p. 91.4-91.9 ºC 
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Spectrum 70. 
1
H NMR of 6,8-dichloro-9-ethyl-9H-purine (133). 
 
 
 
Spectrum 71. 
13
C NMR of 6,8-dichloro-9-ethyl-9H-purine (133). 
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Spectrum 72. HMQC of 6,8-dichloro-9-ethyl-9H-purine (133). 
 
 
 
 
Spectrum 73. HMBC of of 6,8-dichloro-9-ethyl-9H-purine (133). 
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Synthesis of 9-allyl-6,8-dichloro-9H-purine (121a) 
 
Diisopropylamine (0.11 mL, 0.75 mmol) in THF (2 mL) was cooled to -78 ºC under N2-atm. 
1.33M n-BuLi in hexane (0.53 mL, 0.70 mmol) was added dropwise over 10 min and the 
mixture was stirred at -78 ºC under N2-atm for 1 h. 9-allyl-6-chloro-9H-purine 98a (98 mg, 
0.50 mmol) in THF (2 mL) was added dropwise over 10 min and the mixture was stirred at -
78 ºC under N2-atm for 1 h. C2Cl6 (237 mg, 1.00 mmol) in THF (1 mL) was added dropwise 
over 10 min and the mixture was stirred at -78 ºC under N2-atm for 2 min. Sat. aq. NH4Cl (15 
mL) was added and the mixture was left to warm up to r.t., and extracted with EtOAc (3 x 25 
mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO4) and 
evaporated in vacuo. The crude product was purified by flash chromatography eluting with 0-
4% MeOH in DCM gave 25 mg of a mixture of compounds 121a-e as brown oil. 
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9-allyl-6,8-dichloro-9H-purine (121a) 
1
H NMR (CDCl3, 300 MHz): δ 4.89-4.92 (dt, J =1.5 Hz and J = 5.4 Hz, 2H, -CH2), 5.12-5.32 
(m, 2H, =CH2), 5.88-6.01 (m, 1H, =CH), 8.71 (s, 1H, H-2) 
13
C NMR (CDCl3, 300 MHz): δ 46.0 (-CH2), 119.6 (=CH2), 129.7 (=CH), 144.4 (C-8), 
149.6 (C-6), 152.2 (C-2), 152.4 (C-4) 
MS (EI). m/z (rel.%): 227/229/231 (M
+
 100/73/15), 193/195(76/24), 166(23) 
 
δ13C of C-5 was undetermined due to compound 121a being in a mixture of different 
compounds.  
See appendix Spectrum 78 for TOCSY. 
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Scheme 61. 
1
H NMR of 9-allyl-6,8-dichloro-9H-purine (121a). 
 
  
Scheme 62. 
13
C NMR of 9-allyl-6,8-dichloro-9H-purine (121a). 
 
 
139 
 
 
 
Scheme 63. HMQC of 9-allyl-6,8-dichloro-9H-purine (121a). 
 
 
 
Scheme 64. HMBC of 9-allyl-6,8-dichloro-9H-purine (121a). 
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Scheme 65. COSY of 9-allyl-6,8-dichloro-9H-purine (121a). 
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Synthesis of 7-Allyl-6,8-dichloro-7H-purine (130a)  
 
 
A solution of diisopropylamine (0.11 mL, 0.75 mmol) in THF (2 mL) was cooled to -78ºC 
under N2-atm. 1.33 M n-BuLi in hexane (0.53 mL, 0.70 mmol) was added dropwise over 10 
min and the mixture was stirred at -78ºC under N2-atm for 1 h.  7-Allyl-6-chloro-7H-purine 
98b   (98 mg, 0.50 mmol) in THF (2 mL) and added dropwise over 10 min to the reaction 
mixture and stirred at -78ºC under N2-atm for 1 h. C2Cl6 (237 mg, 1.00 mmol THF (1 mL) 
and added dropwise over 10 min to the reaction mixture, sat. aq. NH4Cl (15 mL) was added 
and the mixture was left to warm up to r.t., and extracted with EtOAc (3 x 25 mL). The 
combined organic extracts were washed with brine (20 mL), dried (MgSO4) and evaporated in 
vacuo. The crude product was purified by flash chromatography eluting with 0-2% MeOH in 
DCM gave 41mg (35%) a mixture of 8-dichloro-9-ethyl-9H-purine (130a) and (Z)-6,8-
dichloro-7-(prop-1-en-1-yl)-7H-purine as an off-white solid. 
Ratio of compounds 130a : 130b are 8 : 1. 
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7-Allyl-6,8-dichloro-7H-purine (130a)  
1
H NMR (CDCl3, 300 MHz): δ 4.98-5.05 (dt, J = 17.1 Hz and J = 1.5 Hz, 1H, =CH2-trans), 
5.12-5.14 (dt, J = 3.3 Hz and J = 1.5 Hz, 1H, -CH2), 5.28-5.32 (dt, J = 10.5 Hz and J = 1.5 
Hz), 5.91-6.02 (m, 1H, =CH), 8.82 (s, 1H, H-2) 
13
C NMR (CDCl3, 300 MHz): δ 48.1 (-CH2), 119.0 (=CH2), 124.5 (C-5 or C-8), 130.6 
(=CH), 141.9 (C-4 or C-6), 148.9 (C5 or C-8), 152.8 (C-2), 159.8 (C-4 or C-6) 
MS (EI). m/z (rel.%): 232/230/228 (M
+
 10/62/97), 205/203/201 (0.3/3/5), 195/193 (8/29) 
HR-MS Found 227.9972 calculated for C8H6Cl2N4 227.9970 
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Scheme 66. 
1
H NMR of 7-Allyl-6,8-dichloro-7H-purine (130a).  
 
 
Scheme 67. 
13
C NMR of 7-Allyl-6,8-dichloro-7H-purine (130a).  
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Scheme 68. HMQC 7-Allyl-6,8-dichloro-7H-purine (130a).  
 
 
 
Scheme 69. HMBC 7-Allyl-6,8-dichloro-7H-purine (130a).  
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6.4 Double-bond migration  
Synthesis of 9-(prop-1-en-1-yl)-9H-purin-6-amine (139a-b) 
 
A solution of diisopropylamine (0.38 mL, 2.70 mmol) in dry THF (2 mL) was cooled to -78ºC 
under N2-atm. 1.66 M n-BuLi in hexane (1.50 mL, 2.50 mmol) was added dropwise and the 
mixture was stirred at -78ºC under N2-atm for 1 h.  9-allyl-9H-purin-6-amine 104a   (88 mg, 
0.50 mmol) was dissolved in dry THF (15 mL) and added dropwise to the reaction mixture 
and stirred at -78ºC under N2-atm for 1 h. Water (0.05 mL, 2.50mmol) was added dropwise , 
the mixture was warmed up to r.t. and evaporated in vacuo. The crude product was purified by 
flash chromatography eluting with 0-7 % MeOH in DCM gave 36 mg (41%) recovery of s.m. 
and 52 mg (59%) of 9-(prop-1-en-1-yl)-9H-purin-6-amine (139a-b) as an off-white solid. E/Z 
ratio 1/9 
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(Z)-9-(prop-1-en-1-yl)-9H-purin-6-amine (139a) 
1
H NMR (CDCl3, 300MHz): δ 1.79-1.82 (dd, J = 1.8 Hz and J = 6.9 Hz, 3H, CH3), 5.78-5.88 
(m, 1H, =CH-CH3), 6.23 (bs, 2H, NH2), 6.77-6.82 (dq, J = 1.8 Hz and J = 8.8 Hz, 1H, =CH-
N), 7.88 (s, 1H, H-8), 8.35 (s, 1H, H-2) 
13
C NMR (CDCl3, 75MHz): δ 13.9 (CH3), 119.0 (C-5), 119.8 (=CH-N), 123.5 (=CH-CH3), 
139.7 (C-8), 153.4 (C-2), 155.7 (C-6) 
MS (EI).  m/z (rel.%): 175(M
+ 
100), 148(50), 135(11) 
HR-MS Found 175.0857 calculated for 175.0858 
 
(E)-9-(prop-1-en-1-yl)-9H-purin-6-amine (139b) 
1
H NMR (CDCl3, 300MHz): δ 1.86-1.89 (d, J = 1.8 Hz and J = 6.9 Hz, 3H, CH3), 2.64 (bs, 
2H, NH2), 6.28-6.35 (m, 1H, =CH-CH3), 6.92-6.97 (dq, J = 1.5 Hz and J = 14.1 Hz, 1H, N-
CH=), 7.91 (s, 1H, H-8), 8.35 (s, 1H, H-2) 
δ 13C not reported due to low intensities of HMBC 
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Scheme 70. 
1
H NMR of 9-(prop-1-en-1-yl)-9H-purin-6-amine (139a-b). 
 
 
 
 
 
Scheme 71. 
13
C NMR of 9-(prop-1-en-1-yl)-9H-purin-6-amine (139a-b). 
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Scheme 72. HMQC of 9-(prop-1-en-1-yl)-9H-purin-6-amine (139a-b). 
 
 
 
Scheme 73. HMBC of 9-(prop-1-en-1-yl)-9H-purin-6-amine (139a-b). 
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7. Appendix 
 
Scheme 74. 
1
H NMR of mixture containing (Z)-8-bromo-9-(1-bromoprop-1-en-1-yl)-9H-
purin-6-amine (132b). 
 
Scheme 75.  
13
C NMR of mixture containing (Z)-8-bromo-9-(1-bromoprop-1-en-1-yl)-9H-
purin-6-amine (132b). 
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Scheme 76. HMQC of mixture containing (Z)-8-bromo-9-(1-bromoprop-1-en-1-yl)-9H-purin-
6-amine (132b). 
 
Scheme 77. HMBC of mixture containing (Z)-8-bromo-9-(1-bromoprop-1-en-1-yl)-9H-purin-
6-amine (132b). 
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Scheme 78. TOCSY for mixture of compounds 121a-e. (left to right) sum of spectra (light 
green),  
1
H NMR (orange), compound 121a (light blue), compound 121d (purple), compound 
121e (dark green), compound 121b (red), and compound 121c (dark blue). 
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